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Ischemic cardiomyopathy is characterized by loss of a large number of cardiomyocytes and pervasive 
fibrosis that lead to heart failure. Effective therapies are far from being approved in clinical practice, 
compelling heart transplantation as the unique care. Resettle lost cardiomyocytes, boosting the function 
of cardiac progenitor cells (CPC), is under investigation as a promising therapy, but clinically meaningful 
results are hampered by the pathological traits of the tissue in which CPC reside. Since cells are able to 
sense the external environment through the mechanotransduction process, physical and biological 
alterations characterizing the extracellular matrix (ECM) of the pathologic heart, might lead to an 
improper function of CPC.  
 
Aim 
To investigate if CPC isolated from ischemic hearts presents defects in mechanotransduction.   
 
Methods and Results 
CPC were obtained from healthy donors (healthy CPC) and from heart failure patients (ischemic CPC). 
The transcription profile of healthy and ischemic CPC was analyzed and compared identifying an 
imbalance in genes involved in “Focal adhesion” and “Regulation of actin cytoskeleton” that, 
interestingly, are very closed to mechanotransduction. To test the involvement of these pathways, cells 
were stained with paxillin and phalloidin, a marker respectively of focal adhesion and F-actin. 
Consistently, ischemic CPC displayed differences in cytoskeleton morphology and high number of focal 
adhesions. Given the link between mechanotransduction, stiffness and ECM, we evaluated the responses 
of CPC plated on a soft (16kPa), intermediate (231kPa) and very hard (in order to GPa) substrates coated 
with two different fibronectin (FN) concentrations (1 and 25µg/mL). Data showed that ischemic CPC 
resulted more spread, less polarized and with less branching, displaying moreover a partial indifference 
to stiffness and FN. Interestingly, atomic force microscopy measure of cell stiffness, evidenced that 
ischemic CPC display the same indifference to substrate rigidity. Since all these data demonstrated that 
ischemic CPC behave differently with respect to healthy CPC when exposed to mechanical stimuli, we 
decided to study, in the same conditions, the nuclear shuttling of YAP and MRTF-A, two of the best-
known transducers of these stimuli into biochemical responses. Consistently with previous results, 
ischemic CPC are indifferent to applied stimuli since no differences in YAP and MRTF-A shuttling 
emerged. Moreover, in healthy CPC, but not ischemic CPC, the shuttling of YAP and MRTF-A is 
correlated. Finally, acting on pathways controlling YAP and MRTF-A, we found that healthy and 
ischemic CPC differ in pathways involved in signal transduction and in the degree of responses. 
 
Conclusion 
This study demonstrated that CPC isolated from ischemic hearts are characterized by altered 
mechanotransduction properties. The lost link between YAP and MRTF-A shuttling with physical cues 
and the aberrant response to treatment, suggest that restoring those pathways could result in improved 
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1.1. HEART FAILURE 
 
1.1.1. The burden of heart failure 
 
Heart failure (HF) is a syndrome characterized by the altered ability of the heart to either contract (systolic 
heart failure or heart failure with reduced ejection fraction) to meet the metabolic needs of the body or 
to relax (diastolic heart failure or heart failure with preserved ejection fraction) (Komajda & Lam, 2014). 
The prevalence (number of people affected on total population) of HF is age-dependent, ranging from 
less than 1% of people younger than 60 years to almost 10% of those older than 75 years, as reported by 
the Rochester Epidemiologic Project (Redfield et al., 2003) and by the Rotterdam study (Mosterd et al., 
1999). From these data, it is possible to extrapolate that about 26 million adults worldwide are living with 
heart failure (Bui, Anh, Horwish, Tamara, & Fonarow, Gregg, 2012) making it one of the most 
widespread illnesses after cancer (Torre et al., 2015) and HIV infections (Piot & Quinn, 2013). Across 
the globe, 17-45% of patients admitted to the hospital with a diagnosis of HF die within 1-year of 
admission, while most patients die within 5 years of admission (Bui, Anh et al., 2012). In North America, 
the incidence (newly affected patients per year) ranges from 2 to 5 per 1,000 person-year. In the 
Framingham Heart Study (Levy et al., 2002), the mean incidence of HF is 4.45 per 1,000 person-year, 
whereas in Olmsted cohort (Roger, Weston, Redfield, & al, 2004) the rate is 3.33 per 1,000 person-year. 
A very recent Italian study reported that the overall HF prevalence rate in our country in 2013 was 1.25% 
with estimates increasing with age, achieving 13.36% in people older than 90 years. The overall incidence 
was 1.99 per 1,000 person-year. Similarly, the incidence rate increases with age, especially in people older 
than 65 years (Piccinni et al., 2017).  
The contribution of improved measures in treating heart attacks, which increase the proportion of 
survivors, and the ageing of general population, will lead to an alarming increase in heart failure burden 












A wide range of factors are known that may lead to HF, as reported by The Global Burden of Disease 
Study which determined 17 primary etiologies (Hawkins et al., 2009). Nonetheless, more than two-thirds 
of all cases of HF can be attributed to four conditions: ischemic heart disease, chronic obstructive 
pulmonary disease, hypertensive heart disease, and rheumatic heart disease. In the developed world, 
ischemic heart disease remains the leading cause. 
Ischemic heart disease or Ischemic Cardiopathy (IC) is a pathologic condition caused by coronary 
atherosclerosis, leading, in the worst cases, to myocardial infarction (MI). In the 10 years after an MI, 




1.1.3. Pathology and classification 
 
The American College of Cardiology (ACC) and American Heart Association (AHA) define HF as “a 
complex clinical syndrome that results from any structural or functional impairment of ventricular filling 
or ejection of blood” (Yancy et al., 2013). 
Historically, cardiac dysfunction has been assessed with reference to left ventricular ejection fraction 
(LVEF), accepted as normal over 50-60% values. However, it is now well documented that even patients 
which have a normal range LVEF, but a substantial impairment of diastolic relaxation or filling, may 
show HF syndrome symptoms. This led to classify, clinically, two main types of HF, based on the 
functional status of the heart: heart failure with preserved ejection fraction (HFpEF) and heart failure 
with reduced ejection fraction (HFrEF). Despite a LVEF that range over than 50% and a maintained 
left-ventricular (LV) cavity volume, heart in HFpEF subjects suffers of thickened and stiffened LV wall, 
hence, the ratio of LV mass/end-diastolic volume is high. In contrast, in patients with HFrEF, the LV 
cavity is typically dilatated and muscle fibers are stretched (Ohtani et al., 2012). Recently, a further sub-
class has been created including patients with an LVEF in the range of 40–49% representing a ‘grey area’, 
defined as heart failure with mid-range ejection fraction (HFmrEF) (Andronic, Mihaila, & Cinteza, 2016). 
Howsoever, the end result of either HFrEF, HFpEF and HFmrEF is a fall in cardiac output.  






The New York Heart Association (NYHA) functional classification (Ponikowski et al., 2016) defines four 
functional classes as: 
Class I: HF does not cause limitations to physical activity (ordinary physical activity does not cause 
symptoms); 
Class II: HF causes slight limitations to physical activity (the patients are comfortable at rest, but ordinary 
physical activity results in HF symptoms); 
Class III: HF causes marked limitations of physical activity (the patients are comfortable at rest, but less 
than ordinary activity causes symptoms of HF); 
Class IV: HF patients are unable to carry on any physical activity without HF symptoms or have 
symptoms when at rest. 
 
The American College of Cardiology/American Heart Association (ACC/AHA) staging system (Yancy 
et al., 2013) is defined by the following four stages: 
Stage A: High risk of heart failure, but no structural heart disease or symptoms of heart failure;  
Stage B: Structural heart disease, but no symptoms of heart failure;  
Stage C: Structural heart disease and symptoms of heart failure;  




























1.1.4. Adverse cardiac remodeling 
 
The development of the HF phenotype arises from a group of molecular, cellular and interstitial changes 
that manifest clinically as changes is size, mass, geometry and function of the heart after injury, called 
cardiac remodeling (Cohn, Ferrari, & Sharpe, 2000). Extensive myocardial remodeling is a process that 
occurs in both the infarcted and non-infarcted myocardium, leading to: altered tissue structure, increase 
tissue stiffness and ventricular dysfunction. This process involves abnormalities in energy metabolism 
(Azevedo, Minicucci, Santos, Paiva, & Zornoff, 2013), oxidative stress (Münzel, Gori, Keaney, Maack, & 
Daiber, 2015), inflammation (Epelman, Liu, & Mann, 2015), altered expression or function of contractile 
proteins (Maytin & S. Colucci, 2002), calcium transport (Min & Mark, 2014), neurohormonal activation 
(Florea & Cohn, 2014) and fibrosis (Leask, 2015). 
Remodeling can begin with an acute infarction, leading to myocardial injury and cell death but involves 
a progressive group of changes, that affect the whole organ and were arbitrarily divided into an early 
phase (within 72 hours) and a late phase (beyond 72 hours) (Figure 1.1). 
Early remodeling. In the 3-4 days after the MI and after the massive myocardial necrosis, an influx of 
inflammatory cells leads to the destruction of the collagen scaffolding that helps to maintain ventricular 
shape (Cleutjens, Kandala, Guarda, Guntaka, & Weber, 1995). Infarct expansion results in wall thinning 
and ventricular dilatation, causing diastolic and systolic wall stress, that stimulates the release of 
angiotensin II, which initiates the increases the synthesis of collagen (Sadoshima, Jahn, Takahashi, Kulik, 
& Izumo, 1992) and promotes cardiomyocyte hypertrophy and apoptosis (Watkins, Borthwick, 
Oakenfull, Robson, & Arthur, 2011)(Goldenberg, Grossman, Jacobson, Shneyvays, & Shainberg, 2001). 
The activation of the renin-angiotensin-aldosterone system (RAAS) stimulates the production of atrial 
and brain natriuretic peptides (ANP and BNP) to normalize ventricular filling and pump function. In this 
period, cardiac fibroblasts are recruited to the infarcted site and begin to deposit new collagen matrix that 
contribute to scar formation. 
Late remodeling. Over the months, the main changes involve the viable myocardium. To compensate the 
loss of dead myocardium and preserve cardiac output, the increasing load on the non-infarcted 
myocardium leads to eccentric hypertrophy and LV cavity dilatation. Over the time, these initial 
compensatory mechanism switch to an adverse effect increasing LV size, which causes increasing wall 
stress and further dilatation (SMG Sutton & Sharpe, 2009). 
 
 
Figure 1.1 Schematic representation of factors involved in the progression of ventricular remodeling. 
ECM, extracellular matrix; RAAS, renin-angiotensin-aldosterone system; CO, cardiac output; SVR, systemic 
vascular resistance; LV, left ventricular; and AII, angiotensin II. The figure has been extracted from Martin G. St. 
John Sutton and Norman Sharpe, Left Ventricular Remodeling After Myocardial Infarction: Pathophysiology 



















Evidence from rodent and human studies challenges the view of the heart as a terminally differentiated 
organ (Bergmann et al., 2009). The heart seems to possess some regenerative capacities, that have been 
attributed to endogenous progenitor cell populations recently identified in the adult myocardium by 
several independent laboratories (Barile, Gherghiceanu, Popescu, Moccetti, & Vassalli, 2013; Uchida et 
al., 2013). Intrinsically, this regenerative capacity is insufficient to prevent the progression towards heart 
failure following various insults. To address this limitation, a common strategy has been to deliver 
stem/progenitor cells to the diseased heart through local implantation or promoting systemic migration 
(Segers & Lee, 2008). Since the beginning of this century, scientists have thus experimented the possibility 
to stimulate cardiac regeneration mainly through stem or progenitor cell administration (Schneider, 2016) 
with the primary objective to replace damaged myocardium and restore cardiac function (Witman & 
Sahara, 2018).  
Skeletal myoblast was the first cellular type to be used for this purpose, since their ability to differentiate 
in muscle cells. However, clinical relevance was limited due to their reduced ability to commit to the 
cardiomyocyte fate (Menasché et al., 2008). The recognized differentiation plasticity of bone marrow 
derived stem cells led clinicians to test their potential use in cardiac regeneration. Although the implant 
of these cells produced an improvement in cardiac function, the results obtained were considered modest 
and, partially, contradictory (Fisher, Doree, Mathur, & Martin-Rendon, 2015). The reasons of these 
conclusion were attributed to the mechanism of action of implanted cells (release of extracellular factors) 
(Gnecchi, Zhang, Ni, & Dzau, 2008) rather than their differentiation towards the cardiomyocyte 
phenotype (Wu et al., 2015).  
Recently, embryonic stem cells have been tested for their ability to promote cardiac regeneration. Such 
cells can be induced to differentiate easily in cardiac progenitors and cardiomyocytes and might ensure 
an almost unlimited source of cells to implant in the infarcted heart. However, ethical as well as biological 
issues (teratoma formation and rejection) have limited the use of these cells in clinical practice 
(Sanganalmath & Bolli, 2013). 
A step to overcome these problems arrived thanks at the generation of induced Pluripotent Stem Cells 
(Takahashi & Yamanaka, 2006). Nevertheless, although unconstrained from ethical and rejection issues, 
iPSC efficiency in differentiation in mature cardiomyocytes was considered to be low (Takahashi & 
Yamanaka, 2006). 
A promising set of cell population suitable for cardiac regeneration was found in the pool of 
stem/progenitor cells that resides in heart tissue. Beltrami et al. were the first who discovered self-
renewing c-Kit+ cells in the adult heart, able to differentiate into cardiomyocytes, endothelial cells and 
smooth muscle cells and to support the regeneration of heart tissue (Beltrami et al., 2003). These cells 
harbor the classical markers of stemness (self-renewal, clonogenicity and multipotency) and are able to 
differentiate in myocytes, smooth muscle and endothelial cells (Leri, Kajstura, & Anversa, 2011). 
SCIPIO and CADUCEUS were the first two phase I clinical trials performed to study the safety and the 
potential efficacy of heart stem/progenitor cell for the treatment of patients suffering from ischemic 
heart disease. In 2011, data from the SCIPIO trial demonstrated no mortality or adverse events following 
the intracoronary infusion of autologous c-Kit+ CSC (cardiac stem cell) and improvement in heart 
functions (Bolli et al., 2011; Chugh et al., 2012). However, an important controversy has followed this 
trial. Indeed, the Lancet wrote a letter of concern about the integrity of some data contained in the paper 
(Editors, 2014). Nonetheless, the benefits of CSC were further confirmed by the CADUCEUS trial. In 
this case, cells were initially grown from endomyocardial biopsies as floating cell aggregates (named 
cardiospheres) that are enriched in primitive cells. Subsequently, cardiosphere-derived cells or CDC were 
obtained as cells outgrowing from the cardiospheres when these were attached to adhesive culture dishes. 
Finally, CDC were delivered into the heart of patients with severe LV dysfunction, reducing infarct size 
(Makkar et al., 2012; Malliaras et al., 2014). In the first randomized controlled phase II clinical trial 
PERSEUS the absolute changes in LV function were significantly greater in CDC-treated patients than 
in controls (Ishigami et al., 2017). Therefore, it was demonstrated that the administration of stem cells in 
ischemic hearts is a feasible procedure, devoid of risks in short and midterm nevertheless, there are several 
open questions on using CSC such as the mechanism of action, the dose and the best way of 
administration (Sanganalmath & Bolli, 2013). 
A further approach aims to stimulate endogenously the cardiac stem cells pool (Castaldi et al., 2016; 
Zhang et al., 2016). However, our group and others have observed that, when stem cells are subjected to 
a stressful condition (i.e. any condition other than normal), peculiar stem cell features, such as telomerase 
activity and self-renewal, are lost, while increased apoptotic and cellular senescence rates are observed 
(Cesselli et al., 2011; Lewis-McDougall et al., 2018; Nguyen & Sussman, 2015). Unfortunately, there are 
several factors limiting the success of cardiac regeneration, that often do not (only) rely on the intrinsic 













1.3. EXTRACELLULAR MATRIX 
 
1.3.1. Cardiac ecm components 
 
Stem cells and their daughter progenitor cells reside within the stem cell niche, a specific environment 
arranged to maintain their proper function during life-cycle (Ferraro, Celso, & Scadden, 2010).  
The extracellular matrix (ECM) is a key component of the stem cell niche. Its components embed the 
stem cells residing within, providing the right mechanical scaffold and the right anchor. Stem cell niche 
is intimately connected to the surrounding cardiac tissue, allowing stem cells to respond to signals from 
the outside, as in the case of myocardial injury.   
The cardiac ECM is composed of different proteins, proteoglycans, and glycosaminoglycans that form a 
fibrillar mechanical support in which cells are embedded. These structural components include collagen 
types I, III, and V, as well as elastin. In addition to structural components, the ECM is composed of 
nonstructural elements that regulate important cellular functions, such as adhesion, proliferation, and 
differentiation. These are primarily type IV collagen, laminins, and fibronectin (Jourdan-Lesaux, Zhang, 
& Lindsey, 2010; Matsui, Morimoto, & Uede, 2010). 
 
1.3.2. Effects of ecm in stem/progenitor cell function 
 
The adhesion of cells to the extracellular matrix (ECM) regulates many cellular functions including 
spreading, migration, proliferation and differentiation, thus playing a major role in embryonic 
development, adult tissue homeostasis and disease pathogenesis (Discher, Mooney, & Zandstra, 2009; 
Jaalouk & Lammerding, 2009; Wozniak & Chen, 2009). 
Additionally, as anticipated, environmental factors other than the chemical ones regulate the activity of 
stem cell/progenitor. Indeed, relatively recent works have demonstrated that the differentiation potential 
of MSCs is regulated by both substrate composition (Tan et al., 2010) and stiffness (Engler, Sen, Sweeney, 
& Discher, 2006). Following these pioneering studies, the impact that the substrate stiffness exerts on 
stem cell fate has become a major topic of investigation. Stiffness is defined by the Young’s elastic 
modulus (E, measured in Pascals) which is the force needed to stretch a given material. Of peculiar 
importance for our work, studies conducted employing cardiogenic cells isolated from chick embryos, 
showed an increase by 60% of the myofibril orientation and by 3-fold the Troponin T levels when cells 
were cultured onto support with tunable stiffness compared to those with static stiffness (Young & 
Engler, 2011).Furthermore, embryonic stem cells grown on sections of decellularized cardiac ECM 
differentiate more promptly into cardiomyocytes (Higuchi et al., 2013). In line, it was shown that, when 
MSCs were cultured on ECM substrates coated with different collagen subtypes, Collagen V promoted 
cardiomyogenic differentiation whereas Collagen I and III demonstrated no effect (Tan et al., 2010). 
One of the first studies that evaluated the effects of ECM composition on human c-kit+ CPC was 
conducted by Castaldo, Di Meglio and collaborators, who showed that human c-kit+ cells were more 
abundant in the epicardial/subepicardial regions of the heart. Importantly, epicardial cells could be grown 
as epithelial monolayers only in the presence of either subepicardial fibroblasts or the extracellular matrix 
produced in vitro by cardiac fibroblasts but underwent epithelial to mesenchymal transition and 
expressed c-kit after TGFβ stimulation (Di Meglio et al., 2010).  
Additionally, French at al. analyzed the behavior of rat c-kit+ CPC cultured on decellularized porcine 
ventricular ECM or standard collagen type I (Matsui et al., 2010). They showed that early cardiac genes 
for GATA-binding protein-4 (GATA-4), Nkx2.5, α-myosin heavy chain, and troponin C and T were 
increased when CPCs were cultured for 2 days on cardiac ECM compared to collagen.  Moreover, 
independent laboratories cultured c-kit+ cells isolated from pediatric patients onto 3D structures of rat 
ECM plus fibrin whose stiffness ranged from 2 to 32kPa, showing that the stiffness of the substrate 
influenced their differentiation status, as assessed by evaluating the expression of cardiomyocytes, 
endothelial and smooth muscle cell genes (Williams et al., 2015).   
Altogether these results suggest that, since the commitment of stem cells to mature cell types is mediated 
by heart-specific ECM cues (that include its peculiar structure, elasticity and composition) and the heart 
remodeling process that follows cardiac ischemia leads to dramatic alterations in both stiffness and 
composition of cardiac ECM, cardiac pathology could possibly alter stem/progenitor cell functions by 
altering their niches. 
 
1.3.3. Ecm and cardiac fibrosis 
 
In the healthy heart, fibroblasts maintain ECM homeostasis by preserving tissue organization and 
structure, allowing a uniform excitation of the heart. The myocardial ECM contains a wide range of 
proteins including mainly: fibrillar type I and III collagen, fibronectin, elastin, laminin as well as 
proteoglycans and glycoproteins (McCulloch Christopher A. and Coelho, 2015). The fine balance 
between all these elements is massively disturbed in conditions of heart fibrosis and remodeling. For this 
last concept, it is worth to note that two thirds of heart volume are composed by cardiac fibroblasts 
(Camelliti, Borg, & Kohl, 2005). Being the most abundant cell type in the heart, is reasonable to think 
that after cardiac injury, propelled by the release of ANG II, TGF-β1, IGF-1, and TNF-α, fibroblasts, 
now turned into ECM-producing myofibroblasts, produce a massive deposition of new ECM, leading to 
fibrosis (D. Fan, Takawale, Lee, & Kassiri, 2012; Leask, 2015)(Figure 1.2). 
The fibrosis process is associated with a remodeling of the ECM that, in chronic ischemia, consists of 
increased expression of collagen type I and III plus an abnormal fibril cross-linking. Besides collagen, 
expression of many other ECM components, including elastin, fibrillin, fibronectin, and proteoglycans, 
are also changed (D. Fan et al., 2012). Fibrosis can be distinct in two patterns, the reparative fibrosis, aimed 
at replacing dead cardiomyocytes and the reactive fibrosis that occurs in the perivascular and interstitial space, 
in the absence of cell loss (Weber, Pick, Jalil, Janicki, & Carroll, 1989). 
Reactive fibrosis is triggered by post-MI mechanical stress and induces the expansion of connective tissue 
in areas that are remote from the infarction, leading to enhanced stiffness of the myocardium and to the 
impairment of heart diastolic and systolic functions, thus compromising cardiac output (Diez et al., 2002). 
Heart muscle stiffness is largely determined by the composition of the muscle itself hence, in pathological 
conditions with increased ECM deposition, the muscle is stiffer. Specifically, in normal conditions, the 
heart muscle has a Young’s modulus of about 10-15 kPa whereas fibrotic tissue typically ranges from 20 







Figure 1.2. The linkage between fibroblasts and cardiac fibrosis. Cardiac fibroblasts are widely distributed 
within heart tissue surrounded by cardiomyocytes where they ensure the physiological amount and composition 
of extracellular matrix in the healthy heart. Mechanical stress promotes the transition of fibroblasts to the active 
myofibroblast phenotype, leading to fibrosis, causing cardiac remodeling and compromising cardiac function. 
The figure has been extracted from Herum et al. The Soft- and Hard-Heartedness of Cardiac Fibroblasts: 






Figure 1.3. Representation of the stiffness of organs and fibrotic scars. Stiffness, represented as Young’s 
elastic modulus (E), is a key component to preserve the physiological function of different organs. As clearly 
depicted by the figure, according to E it can be possible to categorize two groups, the parenchymal tissue and the 
bone-like tissue. Fibrosis cause an increasing of E creating a pathological category in which fibrotic heart 
belongs. The figure has been extracted from B. Hinz, Matrix mechanics and regulation of the fibroblast phenotype, 





























Aside from circulating cells in the blood, that are freely to move within the blood vessels, most of the 
body cells are anchored to the extracellular matrix and to other cells. As stated in previous paragraphs, 
the extracellular matrix is an active protagonist in driving the fate of cells in physiologic conditions, as 
well as during disease onset and progression. However, the comprehension of the mechanisms by which 
pathology-related modifications can change the response of cells has been obscure for long time.  
The belief that cells rely to other types of stimuli beyond the classical soluble factors (cytokines or growth 
factors) has arisen from the discovery that the RGD (Arg-Gly-Asp) peptide of fibronectin interacts with 
a cell surface receptor identified, later, as the first integrin (Tamkun et al., 1986). In 1993 it was published 
the first evidence that integrins and focal adhesions cooperate to transmit mechanical forces (N Wang, 
Butler, & Ingber, 1993). Few years later, scientists demonstrated that cells can sense and respond to 
applied forces (N Wang & Ingber, 1994; Zhelev & Hochmuth, 1995). In the 90s, thus, the concept that 
cells are not inert to physical forces but instead, interact with them, generating biochemical responses, 
led to the bloom of the new field of mechanobiology.  
Thus, those pioneering studies have demonstrated that cells are not only able to sense biochemical stimuli 
but also physical factors such as force and matrix elasticity and composition. To respond to various 
mechanical stresses, cells must have sensor molecules (mechanosensors) to translate mechanical forces 
into biochemical signals (mechanotransduction). 
 
1.4.1. Contributors to cellular mechanosensing 
 
A central element in mechanobiology is the cellular “mechanosensing” or the process by which cells 
sense the mechanical signals from the outside. The ability to probe the mechanical properties of the 
extracellular space is mainly based on the actin cytoskeleton and on the adhesion complexes that 
physically connect the cytoskeleton to the ECM. Extracellular forces travel through the ECM via collagen, 
fibronectin and laminin and are sensed actively via mechanosensory proteins such as integrins (Hynes, 
2002), paxillin (Pasapera, Schneider, Rericha, Schlaepfer, & Waterman, 2010), vinculin (Carisey et al., 
2013), p130Cas (Sawada et al., 2006), cytoskeleton (Burridge & Wittchen, 2013; Hayakawa, Tatsumi, & 
Sokabe, 2012) and stretch-activated ion channels (Kobayashi & Sokabe, 2010). Beyond these relevant 
examples, the list of mechanosensory proteins is more remarkable (Martino, Perestrelo, Vinarský, Pagliari, 
& Forte, 2018) leading the understanding of this process very arduous.  
The mechanosensing is just a half of the process that allows the cell to adapt to external stimuli. To be 
effective, mechanical cues are transformed in biological signals such as post-translational modifications 
(Lachowski et al., 2018), intracellular shuttling (Dupont et al., 2011), protein unfolding (del Rio et al., 
2009) and novel interactions (Humphries et al., 2007) between a large number of molecules displaying a 
status change in response to mechanical stimulation.  
Thus, the molecular mechanisms by which cells respond to mechanical stimuli are referred to as 
mechanotransduction. The cellular response to mechanical signals involves reorganization of the 




The cytoskeleton is a dynamic structure that provides mechanical support to the cells, controlling their 
shape and tension homeostasis (Fletcher & Mullins, 2010). The propagation of extracellular and cell-
generated forces is ensured by the regulation of cytoskeleton tension (Discher, Janmey, & Wang, 2005) 
and its disruption can lead to changes in gene expression and the consequent alterations of cell biological 
responses (Tamada, Sheetz, & Sawada, 2004).   
The actin cytoskeleton consists of filamentous actin (F-actin), a helical polymer of globular (G) actin 
molecules, and a large number of actin-binding proteins. Cytoskeleton contractility is ensured by F-actin 
and myosin II held together in complex structures called stress fibers (SF), that are clearly visible in 2D 
substrates (Burridge & Wittchen, 2013). As anticipated, mechanical stress-mediated alterations of the 
actin filaments dynamics can modulate gene expression: when cells adhere to a stiff substrate, the F-actin 
to G-actin ratio increases and stress fibers are formed, causing nuclear translocation and activation of the 
transcriptional co-activator YAP. On the other hand, when cells adhere to a soft substrate or stress fibers 
are inhibited by drug treatment, YAP is retained in the cytoplasm (Halder, Dupont, & Piccolo, 2012). 
Thus, actin cytoskeletal remodeling has the potential to mediate mechanical stress-induced modulation 
of gene expression, playing crucial roles in mechanical force-induced cell proliferation, differentiation as 
well as in distinct pathophysiological processes, including embryogenesis, organogenesis, tissue 
homeostasis, organ size control and cancer progression. 
 
1.4.3. Focal adhesions 
 
The cell surface interface for mechanotransduction processes are Focal Adhesions (FA), specialized 
plasma membrane protein complexes composed of: adhesion receptors, signaling molecules and 
cytoskeletal proteins. The mechanosensing activity of FA consists in perceiving and transducing the 
mechanical cues arising from the extracellular milieu or the extracellular cytoskeleton into biochemical 
signals. Focal adhesion kinase (FAK) is one of the first molecules recruited to the developing FA in 
response to mechanical stimuli. FAK is a 125 kDa tyrosine kinase that exerts its function only when 
localized on FA (Shen & Schaller, 1999). The activation of FAK is accomplished when the clustering into 
focal adhesions enhances its autophosphorylation at Y397 (Schaller et al., 1994). Phosphorylation of FAK 
at Y397 create a docking site for the SH2 domain of Src family kinases which, in turn, together with 
FAK, phosphorylates components of focal adhesion including FAK, paxillin and p130Cas, resulting in 
recruitment of additional signaling intermediates and activation of downstream signaling pathways. The 
main adhesion complexes that are involved in mechanosensing are the integrin-based focal adhesions 
(Winograd-Katz, Fässler, Geiger, & Legate, 2014). Integrins directly and rapidly activate nonreceptor 
protein tyrosine kinases, such as focal adhesion kinase (FAK), Src and Fyn in response to tension and 
stiffness (Carraher & Schwarzbauer, 2013; K. M. Herum, Choppe, Kumar, Engler, & McCulloch, 2017; 
Seong et al., 2013). FAK induces a cascade of signaling events involving ERK1/2 and MAPKs (Hynes, 
2002) and with Src and Fyn facilitates the activation of Rho GTPases through activating guanine 
nucleotide exchange factors (GEFs) and GTPases-activating proteins (GAPs) in response to increased 
tension (Guilluy et al., 2011; Rossman, Der, & Sondek, 2005). 
Extracellular matrix composition drives the expression of precise integrin subsets, that activate different 
signaling cascades and thus, different cellular response (Seetharaman & Etienne-Manneville, 2018). 
During the mechanotransduction process, stress fibers (SF) and FA cooperate and stabilize each other: 
the relocation of FA crosslinker proteins upon mechanical loading fosters SF reinforcement and 
cytoskeletal tension; on the other hand, SF contractility prompt vinculin recruitment to the FA (Fabry, 
Klemm, Kienle, Schäffer, & Goldmann, 2011; Yamashita et al., 2014). SF link to FA at-cell substrate 
contact and are well known to play critical roles in both sensing mechanical forces as well as generating 




The mammalian Rho-family contains approximately 20 members of small GTPases that are key 
molecules in regulating and remodeling the actin cytoskeleton under stress conditions. The family is 
divided in three groups in which RhoA, Rac1 and Cdc42 are the representative molecules for each family, 
and the best studied.  
Rho/Rac1/Cdc42 activity is under the control of the opposing actions of Rho-Guanine nucleotide 
Exchange Factors (GEF) and Rho-GTPase Activating Proteins (GAP) (Bos, Rehmann, & Wittinghofer, 
2007) regulating migration and cytoskeletal shaping by affecting the activities of downstream proteins 
(Ridley, 2015).  
Rho-GEF and Rho-GAP are, in turn controlled by physical extracellular stimuli that regulate actin 
cytoskeleton are extremely different and include soluble factors or physical interactions with neighboring 
cells or matricellular proteins. These signals are sensed by various receptor proteins including G protein-
coupled receptors (GPCRs) (Chiariello, Vaqué, Crespo, & Gutkind, 2010), receptors for integrins and 
transforming growth factor-β (TGF- β) (Ji et al., 2014) (REF) and Receptor Tyrosine Kinases (RTKs) 
(Schiller, 2006).  
Rac1 and Cdc42 mediated the extension of lamellipodia and filipodia, respectively, contributing 
predominantly to cell migration whereas Rho is required to cell adhesion (C D Nobes & Hall, 1999; 
Catherine D. Nobes & Hall, 1995). In general, they act as promoters of both actin nucleation and 
branching, even if, among them, only Rho, through its downstream effector ROCK, is able to promotes 




The Hippo signaling pathway is a complex network of proteins that control organ size via regulation of 
cellular proliferation, survival and differentiation. First discovered in Drosophila, the core of the Hippo 
pathway consists of a pair of highly conserved transcriptional coactivators that in mammals are known 
as YAP and TAZ. Briefly, in mammals, Mst1 and Mst2 activate other kinases (Lats1 and Lats2) that 
phosphorylate the transcriptional activator YAP and TAZ, causing it to be excluded from the nucleus 
and retained in the cytoplasm (Zhu, Li, & Zhao, 2014). YAP and its homologue TAZ are potent 
transcriptional coactivators that associate with various DNA-binding proteins, for example TEAD 
factors, to drive gene transcription (Zhu et al., 2014). YAP cannot bind to DNA directly and it is brought 
to certain gene promoters by partner transcription factors. The TEAD family transcription factors were 
identified as potent DNA-binding partner of YAP. Indeed, a point mutation of YAP (S94A) that 
eliminates its ability to interact with TEADs strongly abolishes YAP-induced gene expression as well as 
YAP induced cellular transformation (Zhao, Ye, et al., 2008). 
In recent years, a plethora molecules and pathways acting upstream of the core Hippo pathway, that 
either activate or inhibit YAP/TAZ, have been discovered. These include different kinases (Yu & Guan, 
2013), Wnt pathway (Varelas et al., 2010) and receptor tyrosine kinases (Reddy & Irvine, 2013), metabolic 
pathways (deRan et al., 2014; Liang et al., 2014; Sorrentino et al., 2014), cell adhesion and cell junction 
proteins, cell polarity proteins, and the state of the actin cytoskeleton (Boggiano & Fehon, 2012).  
The latter is a central signaling system that the cell uses to make essential decisions, such as the decision 
to proliferate, differentiate and maintain stem cell proprieties (Mammoto & Ingber, 2009). Strikingly, 
these mechanical and cytoskeletal inputs represent a central mechanism to control YAP/TAZ activity 
(Figure 1.4) 
The investigation of cell morphology on the regulation of Hippo has shown that when cells are grown 
on confined spaces, YAP is mostly cytoplasmic, whereas when cells are free to spread on the substrate 
YAP is localized to the nucleus (Nardone et al., 2017; Wada, Itoga, Okano, Yonemura, & Sasaki, 2011). 
ECM stiffness is another potent controller of YAP/TAZ translocation. On hard substrates YAP and 
TAZ are predominantly nuclear and become cytoplasmic on softer substrates (Dupont et al., 2011).  
When distinct cell types (including epithelial cells and mesenchymal stem cells) adhere to a stiff substrate 
or are subjected to tensile force, the ratio of F- actin to G-actin increases and actin stress fibers are 
formed, causing nuclear translocation and activation of the transcriptional co-activator YAP. In contrast, 
when these cells adhere to a soft substrates or stress fiber formation is inhibited by ROCK or myosin II 
inhibitors, YAP is phosphorylated by the upstream kinase, LATS, resulting in its inactivation via 
cytoplasmic retention or degradation (Dupont et al., 2011; Halder et al., 2012). In sparsely crowded cell 
cultures, YAP is predominantly localized to the nucleus and in its active un-phosphorylated form. On 
the other hand, in high density cultures Yap is phosphorylated and localized to the cytoplasm (Zhao et 
al., 2007).  
Published works provide compelling evidence for a critical role of actin dynamics in the regulation of 
YAP through mechanical cues. Particularly, by correlating the activity of YAP with actin stress fiber 
formation and showing YAP inactivation by the use of F-actin or Rho inhibitors, but not by inhibiting 
microtubules or Rac1-GEFs (Dupont et al., 2011; Halder et al., 2012; Zhao et al., 2012). 
YAP can also be regulated through G-protein coupled receptors (GPCRs) and serum starvation inhibits 
YAP activity via reduced GPCR signaling. GPCR receptor agonists (e.g., Lysophosphatidic acid (LPA), 
sphingosine-1- phosphate (S1P)) activate YAP/TAZ while epinephrine and glucagon inhibit YAP/TAZ 
via Gs-coupled GPCR signaling (Yu et al., 2012) (Figure 1.5). 
Those studies point the importance of mechanical stress and cytoskeletal organization as dominant 





Figure 1.4 Physical control of transcription factors shuttling. The nuclear translocation of transcription 
factors is finely tuned by physical patterns following an on/off scheme. Yap was the first identified to rely to this 
principle. Picture downloaded from https://www.mechanobio.info 
 
Figure 1.5. Mechanisms of YAP regulation. Mechanical cues controlling yap translocation act in synergy with a 
plethora of different receptors. Picture from Guo et al, YAP/TAZ for cancer therapy: Opportunities and challenges 




















1.4.5.1. Yap biological significance 
 
The Hippo-Yap pathway has been recently identified as a crucial axis in the regulation of organ size and 
shape during organogenesis, as well as a possible modulator of cancer growth (Zhao, Lei, & Guan, 2008). 
It is not surprising, therefore, that mechanical signaling has been linked to the regulation of YAP activity 
in a variety of biological contexts, such as cellular differentiation, fibrosis and cancer.  
The Hippo-YAP pathway plays a critical role in the multipotency and differentiation of embryonic stem 
cells, neuronal progenitors, and intestinal stem cells (Barry et al., 2013; Cao, Pfaff, & Gage, 2008; Lian et 
al., 2010). In vitro, YAP/TAZ activity has been associated with mesenchymal stem cell (MSC) fate 
decision as well as a central regulator of human embryonic stem cell self-renewal through the control of 
SMAD complex shuttling to the nucleus (Mo, Park, & Guan, 2014). More recently, Panciera et al 
demonstrated that transient expression of exogenous YAP or TAZ, converts several differentiated mouse 
cell types to tissue-specific stem/progenitor cells (Panciera et al., 2016). Chromatin immunoprecipitation 
(ChIP) experiments indicated that YAP– TEAD binds to promoters of many stemness-promoting genes 
such as Oct4 (Bora-Singhal et al., 2015). Furthermore, although it seems to be dispensable for self-
renewal it is claimed to be essential for ES differentiation Yap1 is dispensable for self-renewal but 
required for proper differentiation of mouse embryonic stem (ES) cells (Chung et al., 2016). 
Given the functions of YAP in proliferation and stem/progenitor cell expansion a role of YAP in tissue 
regeneration has been postulated. In mouse, postnatal hearts have regeneration ability, which is quickly 
lost after day P7. Interestingly, knockout of Yap impairs regeneration of hearts infarcted on P2, while its 

























Additional transcription factors whose activity is regulated by actin dynamics are already known. 
The Myocardin-Related Transcription Factor A (MRTF-A/MKL-1) is another important 
mechanoresponsive signaling pathway. MRTF-A plays a critical role in transducing Rho/actin signaling 
from the cytoplasm to the nucleus by activating SRF-dependent transcription. In fact, RhoA signaling 
promotes actin polymerization (thus decreasing the concentration of free G-actin), resulting in the 
translocation of MRTF-A from the cytoplasm to the nucleus (Esnault et al., 2014). In line, MRTF-A is 
localized in the cytoplasm and translocate to the nucleus in response to either serum stimulation or other 
signals that promote actin polymerization. Specifically, MRTF is normally sequestered by G-actin in the 
cytoplasm but both mechanical and serum stimuli increase actin polymerization, resulting in the nuclear 
accumulation of MRTF, where it, together with serum-response factor (SRF), activates numerous 
cytoskeletal genes (Vartiainen, Guettler, Larijani, & Treisman, 2007). As shown in figure 1.6, Rho GTPase 
regulates actin cytoskeleton dynamics, promoting the assembly of G-actin in F-actin filaments (see rho 
chapter).  Consistently, the nuclear accumulation of MRTF-A can be inhibited by forced expression of 
non-polymerizing actin mutants (Miralles, Posern, Zaromytidou, & Treisman, 2003). Last, Rho/ actin-
induced nuclear import of MRTFs is also regulated by STARS (striated muscle activator of Rho signaling) 
protein, which binds to F-actin, facilitating translocation of MRTF-A to the nucleus (Kuwahara, 









Figure 1.6 MRTF-A nuclear translocation. MRTF-A shuttling is closely related to the intracellular balance of 
glomerular actin (G-actin) and filamentous actin (F-actin). MRTF-A translocation is inhibited when high 
concentrations of G-actin are present in the cytosol. An increase in the actin bundles, make MRTF-A free to 


















1.4.6.1. Mrtf biological significance 
 
The SRF (serum response factor) transcription factor is an important regulator of cytoskeletal and 
muscle-specific gene expression and MRTF-A is essential for SRF function and, therefore, for SRF 
function (Olson & Nordheim, 2010).  
SRF binds with high affinity and specificity to the palindromic CC(A/T)6GG DNA sequence, called the 
CArG-box (Pellegrini, Tan, & Richmond, 1995) and nearly all smooth muscle-specific genes and many 
cardiac and skeletal muscle genes are controlled by CArG-boxes. Given the plethora of genes encoding 
contractile proteins that are regulated by SRF and members of the myocardin family, it is not surprising 
that mis-regulation of the MRTF/SRF pathway is implicated in many diseases affecting mechanically-
stressed tissues, such as the heart (Ho, Jaalouk, Vartiainen, & Lammerding, 2013; Parlakian et al., 2004). 
MRTF-A/SRF driven gene expression is observed in multiple cell lineages including undifferentiated ES 
cells. Moreover MRTF-A is co-expressed with myocardin in the human heart and aortic fibroblasts (Du 
et al., 2004; D.-Z. Wang et al., 2002). MRTF-A is central in promoting the myofibroblast phenotype, as 
stated in a study in which cardiac fibrosis was determined when MRTF-A-deficient animals were 
subjected to myocardial infarction; MRTF-A-null animals had reduced scar formation after MI (Small et 
al., 2010). Last, the MRTF/SRF axis has implications for the regulation of genes that provide a boost in 












2. RATIONALE AND AIMS 
 
Heart failure (HF) is the term used to describe a clinical condition characterized by the inability of the 
heart to sustain its workload reducing the delivery of a proper blood flow to the body. Population aging 
and improved survival of patient with acute myocardial infarction are leading to a yearly growing 
prevalence and incidence of HF, making it a global pandemic, affecting at least 26 million people 
worldwide.  
So far, the only resolutive care for end stage HF patients is the heart transplantation. Of course, there is 
a manifest imbalance between the number of available donor hearts and patients in the waiting list for an 
organ. Moreover, life expectancy after transplantation is low, compelling the individuation of new 
therapies. 
Advances in stem cell biology has highlighted that the heart is not a terminally differentiated organ, as 
previously thought. In fact, cells with a regenerative potential reside into cardiac tissue. From this 
promising discover, it was suggested that the heart tissue could be regenerated. Thus, new therapies have 
been experimented with the intent to regenerate lost tissue by either administering stem/progenitor cell 
with the potential to differentiated into cardiomyocyte or activating the residents Cardiac Progenitors 
Cell (CPC) pool. 
In last years, many studies, including clinical trials, have been performed to investigate the best source of 
stem cells that needed to be used to achieve the aim. Despite promising results, an evidence of strong 
efficacy is still lacking. Since the experimental use of different stem cell types failed to produce 
considerable amelioration of patient outcome, it was suggested that this partial unsuccess was not due to 
the cells itself, but rather to the milieu in which the cells have to exploit their function. 
Ischemic heart disease, the leading cause of HF, is in fact characterized by a severe loss of cardiomyocytes 
that are replaced by pervasive fibrosis leading to modifications of the extracellular matrix composition 
and stiffness, attributes considered critical for stem cell function (Ahmed & Ffrench-Constant, 2016). In 
this context, mechanotransduction pathways, used by cells to adapt to physical changes, have been 
progressively more investigated. This as a consequence of an increasing body of literature (Ning Wang, 
2017), that shed light on the principal modifications of cell behavior in response to physical stimuli. It 
was demonstrated that physical stimuli mainly act on cytoskeleton dynamics and cell shape that, in turn, 
control the nuclear translocation of proteins known to be a master regulator of cell-ECM interaction (i.e. 
YAP and MRTF-A) (Finch-Edmondson & Sudol, 2016). 
Since dramatic biomechanical changes dominate the ischemic heart, it is essential to understand if such 
extended changes impair the mechanotransductional apparatus of CPC. Aim of this study is, therefore, 
to find pieces of evidence of impaired mechanotransduction pathways in CPC isolated from ischemic 
hearts, comparing them with CPC isolated from healthy hearts.  
More specifically, the project was organized in the following steps: 
1. Identification of altered pathways linked with mechanotransduction, 
2. Characterization of morphological and functional properties in CPC in response to physical 
stimuli, 
3. Evaluation of YAP and MRTF-A nuclear translocation in CPC in response to physical stimuli, 
4. Identification of upstream regulators of YAP and MRTF-A subcellular localization employing 



























3.1. Patient enrollment and ethics 
Patient enrolled for this study have suffered for ischemic-induced end-stage heart failure (stage D AHA 
classification) and underwent cardiac transplantation at the University Hospital of Udine.  
The study, in accordance with the Declaration of Helsinki, was approved by the Ethics Committee of 
Udine (2 August 2011, reference number 47831) and written informed consent was obtained from each 
patient. 
 
3.2. Cardiac progenitor cells isolation  
Human cardiac progenitor cells (CPCs) employed in this study were isolated as in (Beltrami et al., 2007) 
from atrial samples collected from healthy hearts and from explanted ischemic end-stage failing hearts of 
patients undergoing heart transplantation at the University Hospital of Udine. 
Atrial fragments were first mechanically dissociated using scalpels and then enzymatically by incubation 
in a 0.1% Collagenase type II solution (Sigma-Aldrich) for 20 minutes at 37°C in a tube rotator. 
Collagenase activity was stopped by adding 0.5% Bovine Serum Albumin (Sigma Aldrich) in Basic Buffer 
(BB) and, once fragments have sedimented, cell suspension was centrifuged at 300 g for 5 minutes. 
Supernatant was discarded, pellet resuspended in 5 ml of BB and filtered through a pre-wet 40μm strainer 
(BD Falcon). The filtered suspension was centrifuged at 300 g for 5 minutes, supernatant was discarded, 
and cell pellet resuspended in Mesencult (STEMCELL Technologies), added with 1% 
Penicillin/Streptomycin (Gibco – Life Technologies). Isolated cells were finally seeded on dishes 
previously coated with 5μg/ml human fibronectin (Merck-Millipore) and cultured in a 5% CO2 incubator. 
At passage 2 cells were switched to expansion medium. 
 
3.3. Detachment and expansion of CPC 
To detach the cells, the plates were washed with 5ml of HBSS and 2ml of TrypLE Express solution (Life 
Technologies) was added. Cells were incubated until the cells dissociate and 5ml of HBSS were used to 
inactivate enzymatic activity. Cell suspension is centrifugated at 300g for 5 minutes and the supernatant 




3.4. Cell migration – scratch assay 
To evaluate the migration rate of CPC, a scratch assay was set up. Both healthy and ischemic cells were 
plated on 96well-plates coated with 1, 5 or 25µg/ml of fibronectin. When the confluence was reached, 
scratches were created utilizing 10µl tips. Phase contrast images were acquired immediately, at 4 and 8 
hours and analyzed with FIJI software. The rate of cell migration was expressed as average of 4 different 
scratch point and it was calculated as distance traveled (µm), in the interval of time between 4 and 8 hours 
from the creation of the scratch. 
 
3.5. Hydrogel substrate preparation and functionalization 
Hydrogels were prepared mixing different proportions of acrylamide and bis-acrylamide to obtain 
substrates of different stiffness (table 3.1). Hydrogel substrates were prepared onto 12mm glass 
coverslips. The surface of clean coverslips was functionalized with 3-(Trimethoxysilyl) propyl-
methacrylate (M6514, Sigma-Aldrich) diluted in one volume of absolute ethanol to let the polyacrylamide 
attach to the glass. After 2-4 minutes coverslips were washed twice with absolute ethanol and then with 
distilled water. Coverslips were let air-dry. A glass surface was treated with Dichlorodimethylsilane 
(440272, Sigma-Aldrich) to avoid polyacrylamide attachment and used as support to distribute 20 µl of 
polyacrylamide solution on which functionalized coverslips were laid on. At completed polymerization, 
hydrogels were washed at least for 16 hours in distilled water at 4°C before functionalization. 
 
Hydrogel surface were functionalized with 0.1mg/ml of Sulfo-SANPAH solution (22589, Thermofisher) 
and exposed to a UV light source for 20 minutes. Hydrogels were washed twice with sterile PBS, covered 
with a fibronectin solution (1μg/ml or 25μg/ml) and incubated overnight at 4°C. Hydrogels were then 
washed with PBS twice before seeding the cells.  
 





APS TEMED Distilled water 
(ml) 
16 kPa 2.5 0.37 1% 0.1% 7.13 
231 kPa 5 3.75 1% 0.1% 2.25 








3.6. Immunofluorescence analysis 
For immunofluorescence analysis, CPC were fixed in 4% paraformaldehyde for 15 min and then 
permeabilized with 0.3% Triton X–100 in PBS. Samples were then incubated with anti‐YAP antibody 
(1:300, sc‐101199, Santa Cruz Bio) and anti-MRTF-A (1:300, PA5-56557, Life-Technologies) overnight 
at 4°C, followed by incubation with Alexa‐Fluor 488 anti‐mouse and Alexa-Fluor 633 anti-rabbit 
secondary antibodies (1:800, Molecular Probes) at 37°C for 1.30 h. Focal adhesion were stained with anti-
PAXILLIN antibody (1:100, 05-417, Millipore) overnight at 4°C, followed by Alexa-Fluor 633 anti-
mouse secondary antibodies. To visualize cells, actin was stained with rhodamine phalloidin (R415 Life 
Technologies) for 20’ at 37°C and DAPI (4',6-Diamidine-2'-phenylindole dihydrochloride) in Vectashield 
(Vector Laboratories) was used for nuclear staining and mounting. All the images used for analyzed the 
cell shaping and the ratio of YAP and MRTF-A were acquired using an epifluorescence microscope 
(DM6000B, Leica Microsystems) equipped with DFC365FX camera (Leica Microsystems) with a 63X 
immersion oil objective. Images of paxillin for focal adhesion analysis were acquired with a confocal 
microscope (TCS SP8 STED, Leica Microsystems) equipped with a 40X immersion water objective. At 
least 30 cells were measured. 
 
3.7. Atomic force microscopy 
Cells’ forces were measured with an Atomic Force Microscopy (NanoWizard II, JPK instruments, Berlin, 
Germany) coupled with an inverted optical microscope (Axiovert 200; Zeiss). For indentation measures 
“tipless” triangular cantilevers, with spring constant of k=0.32 N m-1 (Nanoworld, Cr/Au back-side 
coating) were used, on which a silica 4.5µm diameter beads where attached using UV sensible light (NOA 
73 Norland Optical Adhesive). Before measures, elastic constant of cantilever was calibrated with 
“thermal noise” method in the fluid chamber. Measures were performed in the fluid chamber at room 
temperature, in which hydrogel or glass supports with cells where placed in advance. For each cell, 15 
curves have been taken for single point with 3 second delay each to another and with a setpoint (relative 








3.8. Real time pcr 
Rna from cell pellet was extracted with RNeasy (Qiagen) according to manufacturer’s instructions. Total 
RNA concentration and quality were determined by measuring the absorbance at 260nm (A260) using a 
Nanodrop spectrophotometer (Nanodrop 1000, Thermo Scientific).  
Prior to retro-transcription, eventual DNA contamination was removed by treatment with DNAse I 
(Invitrogen). cDNA was synthesized using Superscript III, Oligo(dT)12-18, dNTPs mix and RNaseOUT 
(Invitrogen) according to manufacturer’s instruction.  
Real-Time-qPCR analyses were performed on triplicate sampling of retrotranscribed cDNA using a 
LightCycler480 (Roche) and analyzed with the Roche software, version 1.5. Expression levels were 
normalized to GAPDH. Primer sequences used to amplify CYR61, CTGF and ANKRD1 are listed in 
table 3.2. Data are expressed as 2^-(Δct). 
 
GENE  Forward primer  Reverse primer  
CYR61  CCTTGTGGACAGCCAGTGTA  ACTTGGGCCGGTATTTCTTC  
CTGF  AGGAGTGGGTGTGTGACGA  CCAGGCAGTTGGCTCTAATC  
ANKRD1  AGTAGAGGAACTGGTCACTGG  TGGGCTAGAAGTGTCTTCAGAT  
   
Table 3.2 Primer sequences 
 
 
3.9. Drug treatment 
At 4th passage, cells were treated according to what reported in table 3.3. Cells were exposed to drug 16 
hours after seeding. Prior to receive serum free medium, cells were exposed to 16 hours with medium 
with 0.1% serum to avoid cell loss. For a control, cells were treated with the vehicle alone (DMSO). 
 
TREATMENT TARGET [ ] TIME 
CI-1040 MEK 50nM 2h 
FAK inhibitor 14 FAK 10µM 2h 
Latrunculin-A ACTIN 25 µM 2h 
Y-27632 RHO 12.5 µM 2h 
Serum free medium // // 2h 




3.10. Bioinformatic analysis 
List of differential expressed genes obtained from (Gianfranceschi et al., 2016) were subjected to 
bioinformatic analysis with the Gene Ontology Consortium – Enrichment Analysis tool 
(http://geneontology.org/) and KEGG mapper (https://www.genome.jp/kegg/mapper.html).  
 
3.11. Image analysis 
FIJI software was used to analyze all the images for this study. “Cell shape descriptors” function of FIJI 
was used for morphological evaluation of cells. 
Ratio of Yap and Mrtf were calculated as ratio of mean nuclear signal and mean perinuclear signal. 
Nuclear signal was selected with a mask on dapi staining; perinuclear signal was referred to a 3µm zone 
surrounding the nucleus. 
 
3.12. Statistical analysis 
Data are described as median and interquartile range. 
Gaussian distribution of data was assessed employing the Kolmogorov/Smirnov test. Comparison 
among groups with one independent variable was performed with Kruskal/Wallis test followed by 
Dunn’s post-hoc test. Comparison among groups with 2 independent variables was performed employing 
repeated measurements two-way ANOVA followed by Sidak’s multiple comparison test. Correlation 
coefficients (R2) were computed from linear regression curves of data. 
A p<0.05 was considered significant. 
Analysis were conducted with GraphPad Prism 6.0 for Windows. 
 
3.13. Solution and culture media 
Basic Buffer: MEM Joklik (Sigma-Aldrich 56449C), 4,7 g/l HEPES (Sigma-Aldrich), 0,3 g/l Glutamine 
(Sigma-Aldrich), 0,25 g/l Taurine (Sigma-Aldrich), 1% Penicillin/Streptomycin, Insulin 20 U/L (Sigma-
Aldrich), pH 7,4. 
Incubation buffer: (0,5% BSA in Basic Buffer), pH 7,4. 
Expansion medium: 60% DMEM low glucose (Invitrogen), 40% MCDB-201 (Sigma-Aldrich), 1 
mg/ml linoleic acid-BSA (Sigma-Aldrich), dexamethasone 10-9M (Sigma-Aldrich), 2-fosfate ascorbic 
acid 10-4 M (Sigma-Aldrich), 1X Insulin transferrin sodium-selenite (Sigma-Aldrich), 2% Fetal bovine 
serum (FBS; Stem Cell Technologies), 10 ng/ml human-PDGF-BB (Preprotech EC), 10ng/ml human-
EGF (Preprotech, EC). 




4.1. Gene expression and biological analysis 
To evaluate whether cardiac pathology perturbs the mechanosensing capacity of cardiac progenitors 
(CPC), we re-analyzed the transcriptional profiles of CPC isolated from healthy (n=4) and ischemic (n=4) 
hearts that were obtained in a previous study of our group (Gianfranceschi et al., 2016). Only differentially 
expressed genes (DEG) that showed a significant (p ≤ 0.05) expression difference of at least 1.7-fold 
between healthy and ischemic were considered. 372 genes and 423 genes were found to be up-regulated 
and down-regulated in cells from ischemic hearts, respectively.  
To understand the biological function of the results of the transcriptomic analysis, we performed a new 
functional annotation analysis using two different pathways databases: Gene Ontology and KEGG. 
Importantly, Gene Ontology (GO) analysis showed that, with regard to the:  
a) “Biological Process” category, 183 and 189 ontologies resulted to be downregulated and 
upregulated in ischemic cells, respectively (Table S1 and S2). In both groups, the GO term 
“Regulation of cell adhesion” is represented by 38 downregulated genes and by 30 enriched genes. In 
the group of enriched genes, the GO term “Actin cytoskeleton organization” appears, where 21 genes 
were upregulated. 
b) “Molecular Function” category, 7 and 19 ontologies resulted to be downregulated and 
upregulated in ischemic cells, respectively (Table S1 and S2). In agreement with what seen above 
the link with cell adhesion and cytoskeleton is confirmed by genes involved in “Extracellular matrix 
structural constituent” and “Cytoskeletal protein binding”. 
c) “Cellular component” category, 65 and 79 ontologies resulted to be downregulated and 
upregulated in ischemic cells, respectively (Table S1 and S2). A total of 52 genes displayed a 
different expression in the “Focal adhesion” group. Moreover, the “Cytoskeleton” entry included 65 
genes upregulated in ischemic cells. 
Finally, KEGG analysis enabled us to link the list of DEG to specific pathways. Interestingly, among 
others, the enriched pathways comprise the “Focal adhesion” and “Regulation of actin cytoskeleton” gene sets 
(Figure 4.1). 
Altogether, bioinformatic analysis indicated that the expression of genes involved in the regulation of cell 




Figure 4.1 Kegg map analysis. Graphical representation of “Regulation of actin cytoskeleton” and “Focal 
adhesion” pathways. Red and green blocks underline down-regulated and up-regulated genes in ischemic CPC 
respectively. 
 
4.2. Morphological properties of cpc 
Together with cell growth, division and death, cell shape is an indicator of cell health. 
Since both focal adhesions and the cytoskeleton are critical regulators of the proper physical proprieties 
and structure of the cells (Kuo, 2013), we started investigating whether differences in “Focal adhesion” and 
“Regulation of actin cytoskeleton” pathways, resulted in altered cell morphology in vitro.  
To test this hypothesis, we first studied and compared the morphological features of healthy and ischemic 
cells (n=5 each) using the FIJI function Shape Descriptors.  
To avoid the attenuation of possible differences as a consequence of the extensive in vitro culture and to 
ensure that cells had enough space to spread (i.e. to avoid cell contacts), cells were plated in sparse 
conditions and fixed 2 and 4 hours after plating. After seeding, the analysis was performed on cells stained 
with phalloidin, to highlight the F-actin cytoskeleton.  
Morphometric analysis of fluorescent images (Figure 4.2) showed that cells isolated from ischemic hearts 
spread over a significantly higher area of the substrate and displayed a less elongated shape when 
compared with healthy ones at the 4 hours’ time point. Concerning “solidity”, a parameter that describes 
the presence of branches emanating from the cell body (e.g. filipodia and lamellipodia), the major 
difference was apparent at 4 hours, although the value does not reach significance (p=0.08).  
The results of this first morphological evaluation suggest the involvement of pathways controlling 
























4.5. Response to modification of substrate stiffness 
Supported by the pieces of evidence obtained in the previous experiment, we decided to better investigate 
the mechanotransduction properties of CPC. Cytoskeletal dynamics are profoundly influenced by 
external physical factors and matricellular composition, so we decided to force the cells to respond to 
different stimuli with the aim to compare their responses. The stimuli adopted to achieve this purpose 
were the modification of the stiffness of the culture substrate and its fibronectin-coating concentration, 
since these factors mimic the alterations observed in failing hearts. For this specific purpose, cells were 
grown onto either polyacrylamide gels with nominal Young modulus (E) of 16kPa (in the range of muscle 
tissue) and 231kPa (in the range of infarcted cardiac tissue) or on glass coverslips (whose E is GPa) 
(Hiesinger et al., 2012; Sachot & Castano, 2014). 
 
4.5.1. Single substrate comparison 
At 16kPa, the softer stiffness used in this experiment, ischemic and healthy cells displayed an average 
spread area of 1,445µm2 and 3,500 µm2, respectively, with a marked difference at 25 µg/ml of fibronectin 
(Figure 4.6 E). The aspect ratio at 1 µg/ml fibronectin shows no significant differences, whereas at 25 
µg/ml fibronectin, healthy cells are 38% longer than the pathological counterpart (3,01 ± 0,19 vs 2,17 ± 
0,23) (Figure 4.6 F). No significant differences were observed in the solidity parameter (Figure 4.6 G). 
At 231kPa, sharp morphological differences arise between the two population of cells. At 1 as well as 25 
µg/ml fibronectin concentrations, both the area and the aspect ratio are significantly different: cells from 
healthy hearts are extensively spread and more polarized than the pathological counterpart (Figure 4.7 E-
F). For both parameters, variations in fibronectin concentration further increases the differences. This is 
more apparent in dictating the cell polarization differences. At this stiffness, in fact, a higher fibronectin 
concentration is important for sprouting ability, that is significative different in favor of healthy cells 
(Figure 4.7 G). 
When CPC were cultured onto glass coverslips, cells isolated from ischemic hearts showed a larger area 
than healthy cells (Figure 4.8 E), that, in turns, are characterized by a longer shape (Figure 4.8 F) as well 
as marked sprouting at higher fibronectin concentration (Figure 4.8 G). 
4.5.2. Comparison of cpc response to substrate stiffness at constant fibronectin concentrations 
We then compared the global response to stiffness of the two groups of cells as a function of fibronectin, 
finding diametrically opposite behaviors. As shown, in healthy cells, the spreading area does not vary in 
response to incremented substrate stiffness, under both fibronectin concentration conditions (Figure 4.9 
A-B). As opposed, cells obtained from ischemic hearts increase their area as a function of substrate 
stiffness, in particular from 16kPa to 231kPa, and the process is more apparent at lower fibronectin 
concentrations. 
As opposed to what observed with the area parameter, cells obtained from ischemic hearts do not 
respond to variations in fibronectin concentration in terms of elongation and sprouting. Conversely, 
healthy cells are very responsive, with marked differences at 16kPa to 231kPa. 
4.5.3. Comparison of response to fibronectin variations at constant stiffness 
Regarding the effect of fibronectin concentration in cell behavior, we observed that cells isolated from 
ischemic hearts do not vary any of the measured parameter, at any stiffness (Figure 4.10). On the contrary, 
in healthy cells, fibronectin stimulates a response, promoting a strong elongation and branching at 
231kPa. 
Summarizing, healthy cells have a greater ability to polarize and to emit protrusions, compared with cells 
from ischemic hearts, that, in turns, show a larger spread area with the tendency to increase in response 
to stiffness. 

































4.7. Nucleocytoplasmic shuttling of YAP in response to fibronectin 
Since we demonstrated that CPC obtained from healthy and pathologic hearts behave differently when 
exposed to mechanical stimuli, we decided to study one of the best-known transducers of these stimuli 
into a biochemical response (i.e. YAP). The nuclear translocation of this transcriptional co-activator, in 
fact, is closely linked to cytoskeleton rearrangement and tension. 
For this purpose, we initially evaluated the nucleocytoplasmic shuttling of YAP as a function of 
fibronectin concentration. To this aim, we immunofluorescencently labeled CPC, cultured employing the 
above described experimental conditions, and computed the ratio between the mean fluorescence 
intensity of the nuclear signal and the mean intensity of a 3µm large area surrounding the nucleus (i.e. 
nucleus/cytoplasmic ratio or n/c). To avoid the interference due to the contact inhibition of cell growth, 
cells were seeded in sparse conditions and fixed 4 hours thereafter. This time point was chosen since 
maximal differences between the two cell types emerged from previous experiments (see paragraph 4.2, 
“Morphological properties of CPC”). In healthy cells, we recorded an increase in YAP nuclear 
localization when moving from 1 to 25µg/ml of fibronectin (Figure 4.12 H). A similar trend was not 
observed in cells obtained from ischemic hearts, that are insensitive to this stimulus, as suggested by their 
incapacity to regulate the nuclear localization of YAP (Figure 4.12 G). Moreover, this difference in 
sensitiveness to fibronectin is confirmed when the n/c ratios of YAP of CPC obtained from normal and 
pathologic hearts were compared. In fact, healthy cells not only have a functional YAP nuclear shuttling 
















4.12. Identification of the modulators of YAP and MRTF-A pathways by means of 
pharmacologic inhibition of upstream regulators of the pathways 
 
Last, we explored the effects on YAP and MRTF-A in healthy and ischemic cells, acting on pathways 
controlling their nuclear localization. Figure 4.25 summarizes the possible modulators of YAP and 
MRTF-A nuclear shuttling and the interventions that we have tested to assess their involvement in the 
differential regulation of these two factors in the two different cell types. 
Concerning the effect of the described interventions on YAP nuclear translocation, we observed that the 
removal of serum from culture medium is a potent signal that causes the significant downmodulation of 
YAP nuclear localization. Only CPC isolated from pathologic hearts, cultured on 25µg/ml fibronectin 
did not respond to this stimulus. Interestingly, as opposed to serum deprivation, MEK inhibition 
significantly promoted the nuclear localization of YAP in both cell types, under every tested experimental 
condition. Latrunculin-A (Lat-A) treatment, instead, exerted an opposite effect, under every tested 
condition, but on CPC isolated from ischemic hearts cultured on 25µg/ml fibronectin coated substrates. 
Intriguingly, the ROCK inhibitor Y27632 reduced YAP nuclear localization only in healthy cells cultured 
in the presence of 1µg/ml fibronectin. Last, the inhibition of FAK showed no effects on YAP n/c ratio 
(Figure 4.26; 4.27). 
Regarding the effects of these interventions on MRTF-A nuclear localization, we only observed a 
downregulation of the MRTF-A n/c ratio when cells grown on 1µg/ml fibronectin were treated with 
Lat-A. This effect was not observed in CPC isolated from pathologic hearts. Conversely, the effect of 
serum deprivation on MRTF-A nuclear localization was only observed in CPC isolated from failing hearts 
grown on 1µg/ml fibronectin coated dishes (Figure 4.28; 4.29). 
Noteworthy, the analysis of the correlation between YAP and MRTF-A, demonstrated that, in serum-





Figure 4.25 Interventions on YAP - MRTF-A pathways. The cartoon summarizes the key components of 
YAP and MRTF-A shuttling. Interventions are depicted in red boxes. Arrows indicate activation, blunt-end 


































In the last (2016) WHO list of world’s biggest killers, the doleful scepter is hold by ischemic heart disease 
(IHD) claiming almost 10 million lives per year. Despite improvements in the management of this disease, 
new therapies were not successful to restrict the mortality of IHD, that even showed an increase of 
deceased from the beginning of the 21th century (Bui, Anh et al., 2012). Until then, the only therapeutic 
option was the no-resolutive pharmacological treatment that, in the worst cases, did not avoid heart 
transplantation. Given these premises, a promising strategy, which is a candidate to reduce the mortality 
of IHD, is supposed to be cell therapy. This new therapeutic approach has been especially fueled by the 
discovery that heart tissue harbors an own stem cell population, stimulating the idea to regenerate the 
lost myocardium, taking advantage of the innate regenerative potential of stem cell. So far, several studies, 
including some clinical trials, have tested the feasibility to administer different sources of stem cells with 
the intent to modify the natural history of IHD and, possibly, to prevent cardiac transplantation (Witman 
& Sahara, 2018). Unfortunately, despite encouraging results, the primary end point is far from being 
achieved (Fisher et al., 2015).  
Although several controversies, of which the scientific community is aware, concern which are the 
limiting factors of this therapy, there is a consensus to consider the complex modifications of the 
structure of the heart that characterize the progression of cardiac pathology towards heart failure, as the 
culprit of the suppressed potential of stem cell therapy. The ischemic heart, in fact, is characterized by a 
progressive shape remodeling caused by cardiomyocyte hypertrophy, matrix remodeling, and fibrosis. 
The resulting alteration of the extracellular matrix texture specifically describes modifications in both 
ECM composition and in tissue physical properties, that create an unphysiological milieu, uncompliant 
for stem cell function and, thus, for stem cell therapy. In this context, much attention was given to a new 
branch of cell biology, when pioneering studies had confirmed that cells not only rely on the classical 
biological stimuli (i.e. soluble factors) but also on physical cues (i.e. substrate stiffness) to regulate their 
proliferative, migratory and differentiation behaviors (Paluch et al., 2015). Thus, this suggests that the 
pathological soil established in ischemic heart is not permissive to stem cells to effectively regenerate the 
cardiac tissue. 
Our group has already demonstrated that Cardiac Progenitor Cells (CPC) isolated from ischemic hearts 
differ from those isolated from healthy hearts in terms of senescence markers, telomerase activity 
(Cesselli et al., 2011) and autophagic flux (Gianfranceschi et al., 2016) but no data is available regarding 
their ability to sense physical cues. Considering that the physicochemical properties of the ECM can 
affect the cell response and that the ECM of ischemic hearts is altered, we speculated that CPC isolated 
from failing hearts could show an impaired ability to sense the surrounding physical environment. To 
prove this concept, the first step of my work was to obtain pieces of evidence supporting this impairment, 
by analyzing the transcriptomic data generated in our previous works (Gianfranceschi et al., 2016). 
Bioinformatics analysis has revealed that CPC isolated from ischemic hearts account for a total of 89 
differentially expressed genes belonging to the “Regulation of cell adhesion” and “Actin cytoskeletal 
organization” gene-sets. These data were further corroborated by the identification of the enrichment of 
the gene-sets “Focal adhesion” and “Regulation of actin cytoskeleton” among the differentially expressed 
genes. To evaluate the effective dissimilarity between CPC isolated from healthy and ischemic hearts, 
cytoskeleton proprieties were studied at two different time points, analyzing cell shapes. The 
morphological characterization has highlighted that, as a function of time, CPC isolated from ischemic 
hearts significantly differ from the normal counterpart in terms of: spreading area, ability to elongate 
(aspect ratio) and, with less evidence, in the ability to emit protrusions (solidity). As stated before, CPC 
isolated from ischemic hearts are senescent, a condition that is linked with cytoskeleton defects including 
enhanced spreading area (Nishio & Inoue, 2005). However, similar alterations in cell morphology were 
also observed in non-senescent fibroblasts obtained from Achilles tendon of aged mice (Arnesen & 
Lawson, 2006). Since cell elongation, as well as the ability of the cell to spread on the substrate, are 
influenced by cell adhesion (Geiger, Spatz, & Bershadsky, 2009), it is plausible that pathologic CPC are 
characterized by either an altered adhesion strength or an increased cell-substrate contact area. Those 
results were confirmed by the fact that pathologic CPC assemble a significantly higher number of focal 
adhesions to adhere to substrate in comparison to healthy CPC. However, when results were normalized 
by analyzing the fractional surface area of the cell covered by the FA, normal CPC showed a larger area 
covered by FA. In this regard, literature data seem to be partly contradictory. Indeed, while some Authors 
described, in senescent fibroblasts, increased levels of focal adhesions, and actin stress fibers, FAK and 
phospho-FAK (Cho et al., 2004), others showed a downregulation of specific components of the FA (i.e. 
paxillin and c-Src) (Nishio & Inoue, 2005). Additionally, other Authors have shown that FA proteins are 
aberrantly localized in the perinuclear regions, in fibroblasts obtained from aging mice (Arnesen & 
Lawson, 2006). However, most published works did not take into account cell hypertrophy (i.e. they did 
not normalize their data for the cell area or volume). As expected, instead, the migration assay showed 
that healthy CPC migrate faster than ischemic ones, since the number of focal adhesions has been 
inversely correlated to migration speed (Sieg, Hauck, & Schlaepfer, 1999). Interestingly, the migration 
difference is visible only at intermediate levels of adhesiveness (i.e. 5µg/mL fibronectin), which is 
consistent with literature data (DiMilla, Stone, Quinn, Albelda, & Lauffenburger, 1993), suggesting that 
healthy CPC retain a balanced focal adhesion assembly/disassembly ratio indispensable for migration 
(Lauffenburger & Horwitz, 1996) and, importantly, a conserved mechanosensing.  
Several lines of evidence have demonstrated that surface stiffness sensing is mediated by focal adhesions 
(Hoffman, Grashoff, & Schwartz, 2011; Puklin-Faucher & Sheetz, 2009; Schwartz & DeSimone, 2008). 
In line with these findings and as expected by previous results, we demonstrated that pathologic CPC 
behave differently, in terms of cytoskeleton shaping, also when plated on substrates with different 
stiffness adsorbed with different concentration of fibronectin. In fact, on all the stiffness tested (i.e. 
16kPa, 231kPa and Glass), healthy CPC display a smaller spreading area, a higher ability to polarize and 
to emit protrusions, when compared with pathologic CPC. Interestingly, all the differences are slightly 
enhanced by increasing the fibronectin concentration. Differences between healthy and ischemic CPC 
become strengthened when comparing their response to stiffness variation. The results demonstrate that 
pathologic CPC increase their spreading area as a function of substrate stiffness, showing an apparent 
incapacity to polarize and emit cell protrusions. On the contrary, healthy CPC spread over a smaller area, 
but show a superior ability to elongate and sprout. Concerning the effects of fibronectin concentration 
on cell behavior, we observed that only healthy CPC can sense variations in fibronectin concentrations, 
as demonstrated by their greater response on polarization and sprouting at 231kPa and on glass 
respectively. As a whole, these data demonstrate that, cells isolated from ischemic hearts have a different 
perception of the physical environment suggesting an improper crosstalk between mechanical cues and 
nucleus. 
Since it has been shown that cells modulate their intracellular stiffness in accordance with the stiffness of 
the cell substrate, we decided to test if cardiac pathology altered this ability, investigating the mechanical 
properties of CPC by Atomic Force Microscopy. Focusing on the 25µg/ml fibronectin condition we 
noted, as expected, that healthy CPC, but not pathologic CPC, increase their internal forces as a function 
of substrate stiffness, even if the increment reach significance only when cells were cultured on Glass. 
The biochemical mechanisms responsible for the modulation of intracellular stiffness have been 
identified in the FAK/Cas and Rho/ROCK/myosin II pathways (Hoon, Tan, & Koh, 2016). 
Moving from literature data showing that the nucleus/cytoplasmic (n/c) shuttling of YAP is a key 
mechanism of mechanotransduction, able to convey mechanical stimuli into proliferative or 
differentiation responses, we decided to investigate the subcellular localization of this co-transcriptional 
regulator in response to different stimuli (Low et al., 2014). We observed that YAP is translocated in the 
nucleus as a function of fibronectin concentration only in normal CPC, while CPC derived from ischemic 
hearts display a lower level of YAP n/c ratio, compared to healthy CPC. In an independent experiment, 
we demonstrated that, the differences in YAP n/c ratio between healthy and pathologic CPC are lost 
when cells are grown on a soft substrate (16 and 231 kPa). Conversely, differences similar to those 
observed in response to fibronectin concentration were observed, when cells were plated on a Glass 
substrate. Moreover, healthy CPC, but not ischemic CPC, showed to be responsive to increasing substrate 
stiffness, up-modulating YAP translocation. Consistent with previous results, fibronectin concentration 
influenced YAP shuttling only when cells were plated on a Glass substrate and only on healthy CPC. 
These results corroborate those obtained from the characterization of cell morphology, further 
demonstrating the ability of healthy CPC to respond to substrate variation, ability lost in CPC from failing 
hearts. Our results are also consistent with published data, that showed an increased activity of the Hippo 
pathway, leading to increased YAP phosphorylation (and, therefore, its inhibition), in samples obtained 
from failing human hearts of both ischemic and non-ischemic origin (Leach et al., 2017). 
Subsequently, we decided to focus on MRTF-A. This latter is another co-transcriptional regulator that 
binds to the Serum Response Factor (SRF) and responds to variations in substrate stiffness or integrin 
engagement. Furthermore, MRTF-A responds to Rho signals that induce a modification in the ratio 
between G- and F-actin. Specifically, MRTF-A can sense the intracellular levels of G-actin, shuttling 
between the nucleus and the cytoplasm as a consequence of its fluctuations (Foster et al., 2018). Most 
importantly for our work, recent studies have shown that MRTF-A and YAP/TAZ can functionally 
interact (Dupont et al., 2011). Precisely, since MRTF-A/SRF transcriptionally regulates many cytoskeletal 
genes, that are part of the YAP interactome, an indirect pathway cross-talk has been hypothesized. 
Furthermore, it was shown that several genes (e.g. Ctgf, Cyr61, and Ankrd1) contain binding sites for both 
TEAD and SRF, therefore a possible direct interaction between the two co-transcriptional regulators has 
been hypothesized (Foster et al., 2018). For these reasons, we studied the n/c shuttling of MRTF-A under 
the same conditions of stiffness and fibronectin in which YAP was studied. Similarly to what found with 
YAP, CPC obtained from ischemic and healthy hearts did not differ in MRTF-A n/c ratio when grown 
onto softer (16KPa and 231Kpa) substrates, whereas, when CPC were grown on Glass substrate the 
difference became significant. Differently from what we observed for YAP, the effects of fibronectin on 
MRTF-A were not significant in either group of cells. 
Since, from the previous study, a partial overlapping trend of YAP and MRTF-A n/c ratio was suggested 
and driven by the observed functional interaction between MRTF-A and YAP, we decided to evaluate if 
they were coordinately regulated. Interestingly, at 1µg/ml of fibronectin, healthy CPC seeded onto Glass, 
showed that the synergistic translocation of YAP and MRTF-A was significantly more coordinated (in 
terms of R2) in CPC obtained from normal hearts with respect to those obtained from pathologic hearts. 
Concerning cells grown on substrates coated with 25µg/ml fibronectin, the expression of YAP and 
MRTF-A was significantly more coordinated, in normal vs pathologic CPC, grown both on 231kPa gels 
and on glass. 
YAP and MRTF-A n/c ratio data perfectly overlap with AFM data, suggesting that only in healthy cells, 
the link among these factors is maintained (C. X. Li et al., 2016; Morikawa et al., 2015). Lack of evidence 
of an increased intracellular stiffness in cells cultured on 231kPa vs 16kPa in healthy cells did not allow 
us to explain why the correlation between YAP and MRTF-A in these conditions. One possibility is due 
to high inter sample variability and a relatively limited sample size, therefore further experiments are 
required to corroborate these findings. 
Finally, to support nuclear translocation data, we assessed the level of the transcripts of three genes 
known to be regulated by both YAP and MRTF-A. Consistently with what observed in translocation 
experiment, two of three genes were significantly more expressed by normal vs pathologic CPC. 
However, due to the high variability in gene expression and relatively limited number of samples analyzed, 
we did not observe a modulation of gene expression as a function of either substrate stiffness or 
fibronectin concentration. The variability in gene expression could be ascribed to the regulation of the 
three genes by both YAP/TEAD and MRTF-A/SRF pathways. We are now planning to test genes 
regulated in a YAP/TEAD only and MRTF-A/TEAD only fashion, to dissect the contribution of the 
two pathways in regulating target gene expression. 
Last, we explored the contribution of upstream regulators, that control the n/c shuttling of YAP and 
MRTF-A. To achieve this, four drugs (CI-1040, a MEK inhibitor; Latrunculin A, a F-actin inhibitor; 
FAKi14, a Focal adhesion kinase inhibitor; Y27632, a ROCK inhibitor) plus a serum free media condition 
were chosen.  
Despite serum components are strong inductors of YAP nuclear localization, we demonstrated that CPC 
isolated from ischemic hearts are less sensitive, with respect to healthy CPC, to serum stimulation. This 
observation suggests that, in healthy CPC, more than in pathologic CPC, YAP control is strongly driven 
by lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P), the key components of the serum 
that have been shown to promote Yap n/c shuttling (Yu et al., 2012). Noteworthy, LPA exerts its 
function via LPA1 and LPA3 receptors, activating the G-protein 12/13 and its downstream effector Rho 
that, in turn, modulates actin dynamics (Yu et al., 2012). Intriguingly, the downregulation of LPA1 and 
LPA3 exert opposing effects of on the senescence of mesenchymal stem cells, according to recent 
literature data (Kanehira et al., 2016). Rho activation can promote actin polymerization via both 
ROCK/LiM Kinase/cofilin (an actin binding protein that regulates actin depolymerization) and the 
formin pathways (Olson & Nordheim, 2010).Concerning ROCK activity, we have observed that its 
inhibitor y27632 caused the exclusion of YAP only in healthy CPC and not in pathologic CPC, suggesting 
that, in the latter, the Rho/ROCK pathway is less active. However, the Rho/ROCK pathway can also be 
activated by integrins via FAK, integrin linked kinase and Src (Schwartz & Shattil, 2000). Furthermore, it 
has also been shown that substrate stiffness may determine cell stiffening via the FAK/Cas pathway, 
promoting Rac activation and modulating peripheral actin cytoskeletal dynamics (Olson & Nordheim, 
2010). Therefore, it is not surprising that at 25µg/ml of fibronectin, the effect of y27632 in healthy CPC 
is masked. For the same reason, we can speculate that, the lack of serum effect on YAP in pathologic 
CPC grown in the presence of 25µg/ml of fibronectin could be due to integrin activation. 
Concerning the mechanism linking actin polymerization status to the nuclear localization of YAP, it has 
been shown that different members of the MAP4K family of kinases (i.e. MAP4K1/2/3, MAP4K4/6/7 
and MST1/2) respond to a variety of stimuli, including actin depolymerization, phosphorylating 
LATS1/2 that, in turn, phosphorylates YAP, inactivating it (Densham et al., 2009; Meng et al., 2015). 
Since as suggested, healthy CPC have a more active ROCK pathway, as expected, disruption of the actin 
network by Latrunculin-A treatment leads to a nuclear exclusion of YAP in healthy CPC. In pathologic 
CPC, the same effect is visible only at 1µg/ml of fibronectin whereas a slightly, but not significant effect 
was observed at 25µg/ml suggesting that these cells may be more resistant to Latrunculin-A treatment, 
possibly as a result of alternative pathways of YAP activation. 
High matrix stiffness has been associated with a chronically activated FAK/Rho signaling, that, in 
mammary epithelial cells, is coupled with the activation of the Ras/MEK/ERK pathway (Provenzano, 
Inman, Eliceiri, & Keely, 2009). Importantly, a negative feedback loop is promoted by ERK on FAK 
phosphorylation status (Zheng et al., 2009). By testing the effect of a short FAK inhibition, we observed 
no inhibitory effect on YAP nuclear localization in either healthy or pathologic CPC. This result could 
be due to the fact that our experiment was conducted in the presence of serum, therefore the LPA 
stimulatory effect might have masked the FAK inhibitors effects. 
Interestingly, concerning MEK, we found that its inhibition led to an increase in the nuclear localization 
of YAP in both healthy and ischemic CPC. Although intriguing, this piece of information is complex to 
discuss. With reference to our data, MEK/ERK signaling can be induced both via FAK and following 
LPA stimulation via Gi proteins (van Leeuwen et al., 2003). MEK and ERK may also be activated by 
EGF and PDGF (two growth factors present in the expansion medium of CPC) (Shaul & Seger, 2007). 
However, it has been recently shown that these growth factors promote YAP nuclear localization in a 
MEK/ERK independent fashion, via either the phosphatidyl inositol 3 kinase/PDK1 pathway or Src 
family kinases, respectively (R. Fan, Kim, & Gumbiner, 2013; Smoot et al., 2017). Most importantly, it 
has been recently been shown that MEK inhibitors and MEK1 silencing promotes the downregulation 
of beta-transducing repeat containing E3 ubiquitin protein ligase, a ubiquitin transferase that promotes 
the degradation of YAP (L. Li et al., 2013; Zhao, Li, Tumaneng, Wang, & Guan, 2010). Moreover, beyond 
the regulation of YAP thorough ERK, MEK can directly interact with YAP, preventing is degradation 
(L. Li et al., 2013). Our conflicting results suggest that MEK inhibition could have paradoxically promote 
ERK activation rather its inactivation thorough a negative feedback (Spirli et al., 2012). 
Last, concerning MRTF-A n/c shuttling, it is regulated by the binding of this factor to G-actin via its 
RPEL domains. As a consequence of this interaction, the co-transcriptional regulator is retained in the 
cell cytoplasm (Olson & Nordheim, 2010). Therefore, every factor that modifies the availability of G-
actin in the cytoplasm (e.g. by promoting actin polymerization) modulates the n/c shuttling of MRTF-
A. Therefore, serum, Rho/ROCK pathway activity, integrin signaling and FAK may indirectly modulate 
MRTF-A. Consistently, at 1µg/mL fibronectin concentration, actin depolymerization and serum 
deprivation reduced the nuclear localization of MRTF-A in healthy and pathologic CPC, respectively. 
Intriguingly, CPC cultured in the presence of 25µg/mL of fibronectin did not modulate MRTF-A nuclear 
localization in response to inhibitory treatments. In line, recent data indicate that FAK signaling, induced 
by mechanical stimulation, can increase the nuclear accumulation of MRTF-A in fibroblasts (Chan, Arora, 




6. CONCLUDING REMARKS 
 
 
Our work demonstrates that mechanotransduction is altered in CPC isolated from ischemic hearts and 
that these cells display an overall insensitivity to stiffness and to the matricellular protein fibronectin as 
well as a different behavior with respect to healthy CPC. These pieces of evidence are well supported by 
the overlapping trend of the nuclear localization of the two mechanotransduction-related co-transcription 
factor YAP and MRTF-A, whose nuclear translocation seems to be lost in ischemic CPC. Consistently, 
interfering with pathways regulating YAP and MRTF-A gave different results between healthy and 
ischemic CPC. Therefore, these findings suggest that investing in a deeper comprehension of CPC 
mechanotransduction pathways may be essential to train CPC to manage with the hostile environment 
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Table S.1 List of ontologys enriched in genes down-regulated in ischemic CPC 
 
GO biological process complete # expected Fold raw P value FDR 
cellular response to chemical stimulus 114 56.02 2.03 1.55E-13 2.43E-09 
cellular process 373 308.64 1.21 3.33E-13 2.62E-09 
response to organic substance 112 58.17 1.93 9.33E-12 4.90E-08 
Unclassified 23 68.29 .34 2.95E-11 9.28E-08 
biological process 408 362.71 1.12 2.95E-11 1.16E-07 
response to chemical 147 87.75 1.68 5.17E-11 1.36E-07 
cellular response to organic substance 92 45.59 2.02 1.64E-10 3.68E-07 
cellular metabolic process 248 183.75 1.35 8.54E-10 1.68E-06 
regulation of cell adhesion 38 13.42 2.83 2.42E-08 3.81E-05 
cellular response to stimulus 186 130.37 1.43 2.37E-08 4.14E-05 
positive regulation of biological process 174 121.09 1.44 7.50E-08 9.08E-05 
organonitrogen compound metabolic process 165 113.02 1.46 7.24E-08 9.49E-05 
cellular component organization or biogenesis 168 115.73 1.45 6.72E-08 9.61E-05 
biological regulation 303 248.07 1.22 8.85E-08 9.95E-05 
cellular component organization 163 112.14 1.45 1.25E-07 1.15E-04 
negative regulation of biological process 154 104.13 1.48 1.14E-07 1.20E-04 
metabolic process 258 202.47 1.27 1.24E-07 1.22E-04 
positive regulation of cellular protein metabolic process 64 31.87 2.01 1.66E-07 1.45E-04 
regulation of cellular protein metabolic process 90 51.60 1.74 2.10E-07 1.57E-04 
positive regulation of cellular process 156 106.86 1.46 2.01E-07 1.58E-04 
localization 164 113.76 1.44 1.93E-07 1.60E-04 
regulation of biological process 288 234.36 1.23 2.52E-07 1.81E-04 
response to stimulus 222 169.07 1.31 3.44E-07 2.35E-04 
positive regulation of protein metabolic process 66 33.98 1.94 3.65E-07 2.39E-04 
regulation of biological quality 122 78.47 1.55 4.21E-07 2.65E-04 
positive regulation of macromolecule metabolic process 107 66.28 1.61 5.50E-07 3.21E-04 
organic substance metabolic process 246 193.13 1.27 5.43E-07 3.29E-04 
regulation of protein metabolic process 95 56.80 1.67 6.33E-07 3.56E-04 
positive regulation of nitrogen compound metabolic process 103 63.39 1.62 6.98E-07 3.79E-04 
system development 131 87.46 1.50 9.12E-07 4.63E-04 
regulation of cell proliferation 63 32.59 1.93 9.08E-07 4.76E-04 
positive regulation of cellular metabolic process 105 65.63 1.60 1.02E-06 5.00E-04 
positive regulation of metabolic process 111 71.36 1.56 1.68E-06 8.03E-04 
cellular protein metabolic process 115 74.99 1.53 1.96E-06 8.82E-04 
regulation of metabolic process 185 137.34 1.35 1.94E-06 8.96E-04 
response to stress 108 69.27 1.56 2.41E-06 1.05E-03 
transport 132 90.10 1.46 2.91E-06 1.21E-03 
response to oxygen-containing compound 58 30.23 1.92 2.85E-06 1.21E-03 
regulation of cellular process 269 220.25 1.22 3.46E-06 1.30E-03 
regulation of signaling 110 71.65 1.54 3.40E-06 1.30E-03 
anatomical structure development 150 106.43 1.41 3.58E-06 1.31E-03 
regulation of macromolecule metabolic process 173 127.26 1.36 3.36E-06 1.32E-03 
establishment of localization 134 92.44 1.45 3.70E-06 1.32E-03 
negative regulation of cellular process 135 93.09 1.45 3.80E-06 1.33E-03 
regulation of cell migration 38 16.39 2.32 3.31E-06 1.34E-03 
regulation of cell communication 109 70.97 1.54 4.18E-06 1.40E-03 
response to endogenous stimulus 56 28.86 1.94 4.10E-06 1.40E-03 
enzyme linked receptor protein signaling pathway 34 14.05 2.42 4.32E-06 1.42E-03 
regulation of multicellular organismal process 96 60.16 1.60 4.74E-06 1.52E-03 
positive regulation of cell adhesion 24 8.13 2.95 5.12E-06 1.61E-03 
regulation of cellular metabolic process 171 126.48 1.35 6.85E-06 2.11E-03 
developmental process 156 113.04 1.38 7.17E-06 2.17E-03 
multicellular organism development 140 99.10 1.41 8.31E-06 2.42E-03 
regulation of response to stimulus 125 85.62 1.46 8.17E-06 2.43E-03 
primary metabolic process 233 186.27 1.25 9.29E-06 2.66E-03 
cellular response to endogenous stimulus 47 23.43 2.01 9.67E-06 2.72E-03 
nitrogen compound metabolic process 223 176.60 1.26 1.01E-05 2.79E-03 
cellular catabolic process 63 35.19 1.79 1.23E-05 3.33E-03 
regulation of cell motility 38 17.53 2.17 1.39E-05 3.72E-03 
regulation of developmental process 82 50.51 1.62 1.54E-05 3.97E-03 
transmembrane receptor protein tyrosine kinase signaling pathway 26 9.93 2.62 1.57E-05 3.98E-03 
cellular localization 79 48.30 1.64 1.53E-05 4.02E-03 
positive regulation of proteolysis 21 7.09 2.96 1.88E-05 4.70E-03 
regulation of cellular component movement 40 19.19 2.08 1.96E-05 4.82E-03 
regulation of protein catabolic process 22 7.72 2.85 2.11E-05 5.12E-03 
positive regulation of cell migration 25 9.61 2.60 2.49E-05 5.95E-03 
catabolic process 68 40.04 1.70 2.62E-05 6.15E-03 
regulation of signal transduction 97 63.82 1.52 2.84E-05 6.58E-03 
extracellular structure organization 21 7.35 2.86 3.14E-05 7.17E-03 
regulation of nitrogen compound metabolic process 162 122.16 1.33 4.03E-05 9.06E-03 
organelle organization 100 67.27 1.49 4.33E-05 9.59E-03 
sensory perception of chemical stimulus 0 10.65 < 0.01 4.43E-05 9.68E-03 
regulation of locomotion 39 19.09 2.04 4.97E-05 9.77E-03 
cellular macromolecule metabolic process 174 133.40 1.30 4.92E-05 9.81E-03 
cellular response to cytokine stimulus 39 19.07 2.05 4.92E-05 9.93E-03 
negative regulation of cell proliferation 31 13.87 2.24 5.26E-05 9.97E-03 
positive regulation of molecular function 61 35.54 1.72 4.63E-05 9.98E-03 
positive regulation of cellular protein catabolic process 12 2.83 4.25 5.22E-05 1.00E-02 
positive regulation of phosphate metabolic process 44 22.67 1.94 4.91E-05 1.00E-02 
cholesterol homeostasis 9 1.54 5.86 4.73E-05 1.01E-02 
sterol homeostasis 9 1.56 5.78 5.20E-05 1.01E-02 
positive regulation of phosphorus metabolic process 44 22.67 1.94 4.91E-05 1.02E-02 
monocarboxylic acid transport 12 2.81 4.28 4.89E-05 1.03E-02 
cell surface receptor signaling pathway 77 48.34 1.59 5.87E-05 1.10E-02 
protein metabolic process 126 90.41 1.39 6.17E-05 1.12E-02 
regulation of cellular protein catabolic process 16 4.90 3.27 6.27E-05 1.12E-02 
positive regulation of locomotion 26 10.65 2.44 6.15E-05 1.13E-02 
vesicle-mediated transport 65 38.75 1.68 6.09E-05 1.13E-02 
detection of chemical stimulus 0 10.22 < 0.01 6.52E-05 1.15E-02 
positive regulation of protein modification process 46 24.66 1.87 6.75E-05 1.18E-02 
regulation of cell death 59 34.21 1.72 7.07E-05 1.22E-02 
positive regulation of cell motility 25 9.98 2.51 7.21E-05 1.23E-02 
positive regulation of cell-substrate adhesion 11 2.48 4.44 7.37E-05 1.23E-02 
regulation of cell-cell adhesion 21 7.82 2.68 7.31E-05 1.24E-02 
tube development 35 16.69 2.10 7.83E-05 1.30E-02 
regulation of phosphorus metabolic process 59 34.74 1.70 8.35E-05 1.34E-02 
regulation of phosphate metabolic process 59 34.70 1.70 8.21E-05 1.35E-02 
positive regulation of protein catabolic process 15 4.49 3.34 8.32E-05 1.35E-02 
positive regulation of catalytic activity 51 28.57 1.78 8.73E-05 1.39E-02 
regulation of primary metabolic process 164 125.48 1.31 9.03E-05 1.39E-02 
positive regulation of cellular component movement 25 10.26 2.44 8.95E-05 1.39E-02 
positive regulation of proteasomal ubiquitin-dependent protein catabolic process 9 1.68 5.36 8.91E-05 1.40E-02 
response to external stimulus 67 40.97 1.64 9.29E-05 1.42E-02 
positive regulation of proteasomal protein catabolic process 10 2.11 4.74 9.43E-05 1.43E-02 
regulation of phosphorylation 54 30.77 1.76 1.01E-04 1.51E-02 
regulation of T cell activation 18 6.25 2.88 1.03E-04 1.53E-02 
regulation of catalytic activity 73 45.96 1.59 1.09E-04 1.60E-02 
response to cytokine 40 20.79 1.92 1.10E-04 1.61E-02 
negative regulation of cell death 40 20.81 1.92 1.12E-04 1.61E-02 
regulation of cell-substrate adhesion 14 4.14 3.38 1.27E-04 1.81E-02 
positive regulation of response to stimulus 74 47.36 1.56 1.37E-04 1.91E-02 
regulation of cellular catabolic process 32 15.36 2.08 1.36E-04 1.91E-02 
positive regulation of cellular catabolic process 19 6.98 2.72 1.36E-04 1.92E-02 
cytokine-mediated signaling pathway 28 12.68 2.21 1.53E-04 1.98E-02 
positive regulation of signal transduction 55 32.36 1.70 1.52E-04 1.99E-02 
organonitrogen compound biosynthetic process 51 29.09 1.75 1.47E-04 1.99E-02 
protein localization to endoplasmic reticulum 11 2.70 4.07 1.51E-04 2.00E-02 
regulation of body fluid levels 24 10.02 2.40 1.49E-04 2.00E-02 
regulation of substrate adhesion-dependent cell spreading 7 1.04 6.70 1.55E-04 2.01E-02 
extracellular matrix organization 18 6.45 2.79 1.51E-04 2.01E-02 
regulation of leukocyte cell-cell adhesion 17 5.86 2.90 1.47E-04 2.01E-02 
organic substance catabolic process 58 34.45 1.68 1.58E-04 2.02E-02 
detection of chemical stimulus involved in sensory perception 0 9.52 < 0.01 1.47E-04 2.02E-02 
regulation of molecular function 94 64.50 1.46 1.76E-04 2.23E-02 
positive regulation of substrate adhesion-dependent cell spreading 6 .74 8.14 1.80E-04 2.26E-02 
regulation of proteolysis 33 16.18 2.04 1.82E-04 2.27E-02 
regulation of programmed cell death 54 31.73 1.70 1.87E-04 2.31E-02 
positive regulation of phosphorylation 40 21.22 1.88 1.91E-04 2.35E-02 
animal organ development 92 63.15 1.46 2.05E-04 2.50E-02 
regulation of catabolic process 35 17.74 1.97 2.16E-04 2.61E-02 
sensory perception of smell 0 9.18 < 0.01 2.20E-04 2.65E-02 
response to wounding 26 11.47 2.27 2.29E-04 2.73E-02 
regulation of immune system process 53 31.36 1.69 2.51E-04 2.84E-02 
response to vitamin E 4 .25 16.27 2.41E-04 2.85E-02 
symbiont process 29 13.60 2.13 2.50E-04 2.85E-02 
positive regulation of ubiquitin-dependent protein catabolic process 9 1.95 4.63 2.48E-04 2.85E-02 
protein modification process 91 62.49 1.46 2.48E-04 2.87E-02 
cellular protein modification process 91 62.49 1.46 2.48E-04 2.89E-02 
biosynthetic process 131 97.56 1.34 2.46E-04 2.89E-02 
multicellular organismal process 174 137.60 1.26 2.58E-04 2.90E-02 
positive regulation of proteolysis involved in cellular protein catabolic process 10 2.42 4.14 2.64E-04 2.93E-02 
secretion 41 22.22 1.84 2.63E-04 2.93E-02 
protein modification by small protein conjugation or removal 37 19.48 1.90 2.71E-04 2.94E-02 
regulation of multicellular organismal development 63 39.29 1.60 2.71E-04 2.96E-02 
positive regulation of cell communication 58 35.35 1.64 2.70E-04 2.97E-02 
intracellular transport 53 31.63 1.68 2.77E-04 2.99E-02 
positive regulation of signaling 58 35.52 1.63 2.84E-04 3.04E-02 
positive regulation of cell-cell adhesion 15 5.08 2.95 2.99E-04 3.16E-02 
anatomical structure morphogenesis 66 41.93 1.57 2.98E-04 3.17E-02 
cellular protein localization 52 30.64 1.70 3.08E-04 3.23E-02 
detection of chemical stimulus involved in sensory perception of smell 0 8.54 < 0.01 3.14E-04 3.27E-02 
cellular macromolecule localization 52 30.83 1.69 3.21E-04 3.33E-02 
regulation of cytokine production 28 13.05 2.15 3.30E-04 3.39E-02 
lipid homeostasis 10 2.50 4.00 3.38E-04 3.41E-02 
translational initiation 11 2.99 3.68 3.41E-04 3.42E-02 
negative regulation of cellular component organization 29 14.03 2.07 3.37E-04 3.42E-02 
cellular response to growth factor stimulus 23 10.04 2.29 3.37E-04 3.44E-02 
viral process 26 12.06 2.16 3.64E-04 3.62E-02 
xenobiotic metabolic process 10 2.54 3.94 3.82E-04 3.78E-02 
regulation of proteasomal protein catabolic process 12 3.58 3.35 4.15E-04 4.09E-02 
cellular response to oxygen-containing compound 37 19.66 1.88 4.35E-04 4.25E-02 
organic substance biosynthetic process 128 96.35 1.33 4.58E-04 4.45E-02 
protein modification by small protein removal 16 5.90 2.71 4.64E-04 4.48E-02 
blood coagulation 16 5.92 2.70 4.81E-04 4.50E-02 
regulation of T cell cytokine production 5 .57 8.72 4.75E-04 4.50E-02 
response to growth factor 24 10.67 2.25 4.71E-04 4.52E-02 
cell communication 140 107.25 1.31 4.80E-04 4.53E-02 
macromolecule metabolic process 194 158.00 1.23 4.87E-04 4.53E-02 
response to increased oxygen levels 5 .57 8.72 4.75E-04 4.53E-02 
cellular response to xenobiotic stimulus 12 3.67 3.27 5.02E-04 4.65E-02 
regulation of proteolysis involved in cellular protein catabolic process 13 4.22 3.08 5.11E-04 4.70E-02 
regulation of apoptotic process 52 31.42 1.65 5.18E-04 4.71E-02 
macromolecule localization 73 48.46 1.51 5.21E-04 4.71E-02 
coagulation 16 5.96 2.68 5.16E-04 4.72E-02 
nervous system development 70 46.11 1.52 5.28E-04 4.75E-02 
regulation of localization 79 53.81 1.47 5.45E-04 4.85E-02 
negative regulation of response to stimulus 52 31.61 1.65 5.43E-04 4.86E-02 
response to interferon-gamma 12 3.71 3.24 5.51E-04 4.87E-02 
regulation of cell morphogenesis 22 9.77 2.25 5.57E-04 4.90E-02 
positive regulation of protein phosphorylation 37 20.28 1.82 5.64E-04 4.93E-02 
hemostasis 16 6.02 2.66 5.73E-04 4.96E-02 
blood vessel development 22 9.79 2.25 5.71E-04 4.96E-02 
      
      
GO molecular function complete # expected Fold raw P value FDR 
protein binding 327 240.94 1.36 1.87E-17 8.71E-14 
binding 379 308.62 1.23 1.05E-15 2.45E-12 
molecular function 406 359.33 1.13 2.72E-11 3.17E-08 
Unclassified 25 71.67 .35 2.72E-11 4.22E-08 
structural molecule activity 42 16.69 2.52 1.21E-07 1.13E-04 
signaling receptor binding 61 34.31 1.78 1.58E-05 1.05E-02 
catalytic activity 165 122.82 1.34 1.57E-05 1.22E-02 
extracellular matrix structural constituent 12 2.85 4.21 5.57E-05 3.24E-02 
ion binding 167 127.87 1.31 7.90E-05 4.09E-02 
      
      
GO cellular component complete # expected Fold raw P value FDR 
cytoplasmic part 296 197.56 1.50 4.14E-21 4.20E-18 
intracellular part 380 295.42 1.29 4.08E-21 8.27E-18 
cytoplasm 330 235.55 1.40 1.42E-20 9.57E-18 
membrane-bounded organelle 344 253.29 1.36 5.36E-20 2.72E-17 
intracellular 381 301.10 1.27 1.62E-19 6.55E-17 
organelle 359 275.58 1.30 1.85E-18 6.25E-16 
intracellular organelle 336 258.66 1.30 6.25E-15 1.81E-12 
intracellular membrane-bounded organelle 300 222.24 1.35 5.41E-14 1.37E-11 
organelle part 271 194.20 1.40 2.04E-13 4.60E-11 
intracellular organelle part 265 188.18 1.41 2.37E-13 4.82E-11 
vesicle 141 77.51 1.82 3.42E-13 6.30E-11 
cell 402 348.86 1.15 6.30E-13 1.07E-10 
cytosol 171 103.91 1.65 1.80E-12 2.60E-10 
cell part 401 348.31 1.15 1.73E-12 2.69E-10 
Unclassified 10 47.44 .21 2.07E-11 2.62E-09 
cellular component 421 383.56 1.10 2.07E-11 2.79E-09 
endomembrane system 151 90.78 1.66 4.00E-11 4.77E-09 
endoplasmic reticulum 82 38.67 2.12 1.83E-10 2.06E-08 
extracellular space 120 67.70 1.77 2.59E-10 2.76E-08 
extracellular region part 124 71.53 1.73 4.35E-10 4.41E-08 
extracellular organelle 87 43.36 2.01 5.81E-10 5.36E-08 
extracellular vesicle 87 43.32 2.01 5.64E-10 5.45E-08 
extracellular exosome 85 42.91 1.98 2.16E-09 1.91E-07 
membrane-enclosed lumen 162 107.00 1.51 7.92E-09 6.18E-07 
intracellular organelle lumen 162 107.00 1.51 7.92E-09 6.42E-07 
organelle lumen 162 107.00 1.51 7.92E-09 6.69E-07 
extracellular region 137 88.12 1.55 5.03E-08 3.78E-06 
intracellular vesicle 86 46.97 1.83 5.98E-08 4.18E-06 
cytoplasmic vesicle 86 46.91 1.83 5.85E-08 4.24E-06 
endoplasmic reticulum part 57 27.45 2.08 3.10E-07 2.10E-05 
cell-substrate adherens junction 26 8.34 3.12 7.89E-07 5.16E-05 
protein-containing complex 157 110.34 1.42 8.92E-07 5.65E-05 
cell-substrate junction 26 8.42 3.09 9.38E-07 5.76E-05 
focal adhesion 25 8.28 3.02 2.21E-06 1.32E-04 
adherens junction 29 11.02 2.63 4.58E-06 2.66E-04 
anchoring junction 29 11.35 2.56 7.80E-06 4.40E-04 
cell cortex 20 6.29 3.18 1.14E-05 6.23E-04 
endoplasmic reticulum membrane 43 21.75 1.98 3.52E-05 1.88E-03 
endoplasmic reticulum subcompartment 43 21.86 1.97 3.75E-05 1.95E-03 
collagen-containing extracellular matrix 17 5.28 3.22 4.49E-05 2.28E-03 
nuclear outer membrane-endoplasmic reticulum membrane network 43 22.22 1.93 6.67E-05 3.30E-03 
nucleus 189 149.48 1.26 1.01E-04 4.87E-03 
nuclear lumen 117 83.82 1.40 1.36E-04 6.42E-03 
organelle subcompartment 58 34.58 1.68 1.62E-04 7.45E-03 
nucleoplasm 102 71.40 1.43 1.89E-04 8.52E-03 
nuclear part 125 91.97 1.36 2.28E-04 1.01E-02 
extracellular matrix 22 8.87 2.48 2.36E-04 1.02E-02 
non-membrane-bounded organelle 118 86.09 1.37 2.59E-04 1.07E-02 
intracellular non-membrane-bounded organelle 118 85.95 1.37 2.55E-04 1.08E-02 
Golgi apparatus 53 31.61 1.68 2.75E-04 1.11E-02 
cytoplasmic vesicle lumen 18 6.88 2.62 3.18E-04 1.26E-02 
vesicle lumen 18 6.90 2.61 3.29E-04 1.28E-02 
cell junction 46 26.14 1.76 3.42E-04 1.31E-02 
transferase complex 33 16.63 1.98 3.64E-04 1.37E-02 
nuclear stress granule 3 .10 29.29 4.17E-04 1.54E-02 
endosome 35 18.31 1.91 4.29E-04 1.55E-02 
pigment granule 9 2.15 4.18 4.92E-04 1.72E-02 
secretory granule lumen 17 6.55 2.59 5.06E-04 1.74E-02 
melanosome 9 2.15 4.18 4.92E-04 1.75E-02 
vacuole 31 15.81 1.96 6.99E-04 2.36E-02 
catalytic complex 48 28.92 1.66 9.18E-04 3.05E-02 
endosome lumen 5 .70 7.18 1.04E-03 3.42E-02 
vacuolar lumen 11 3.48 3.16 1.12E-03 3.43E-02 
ubiquitin ligase complex 15 5.80 2.59 1.09E-03 3.44E-02 
secretory granule 32 17.10 1.87 1.11E-03 3.46E-02 
cytoplasmic region 22 10.08 2.18 1.08E-03 3.48E-02 
fibrinogen complex 3 .18 16.27 1.54E-03 4.67E-02 
      
 
Table S.2 List of ontologys enriched in genes up-regulated in ischemic CPC 
GO biological process complete # expected Fold raw P value FDR 
cellular component organization or biogenesis 166 102.30 1.62 3.93E-12 3.09E-08 
cellular component organization 163 99.13 1.64 2.37E-12 3.73E-08 
cellular process 329 272.83 1.21 1.56E-11 8.20E-08 
negative regulation of biological process 149 92.05 1.62 1.71E-10 6.72E-07 
biological process 361 320.63 1.13 3.42E-10 8.98E-07 
Unclassified 20 60.37 .33 3.42E-10 1.08E-06 
regulation of cell proliferation 65 28.81 2.26 1.36E-09 3.06E-06 
response to stress 106 61.24 1.73 9.84E-09 1.55E-05 
multicellular organism development 138 87.60 1.58 9.17E-09 1.60E-05 
system development 126 77.32 1.63 8.69E-09 1.71E-05 
anatomical structure development 144 94.08 1.53 2.13E-08 3.05E-05 
localization 151 100.56 1.50 3.02E-08 3.96E-05 
positive regulation of apoptotic process 33 11.05 2.99 5.74E-08 6.02E-05 
negative regulation of macromolecule metabolic process 84 45.88 1.83 5.55E-08 6.24E-05 
negative regulation of cell proliferation 35 12.26 2.86 6.44E-08 6.33E-05 
positive regulation of programmed cell death 33 11.15 2.96 7.13E-08 6.60E-05 
regulation of smooth muscle cell proliferation 15 2.37 6.32 5.49E-08 6.64E-05 
organelle organization 101 59.46 1.70 7.76E-08 6.78E-05 
negative regulation of cellular process 128 82.29 1.56 8.52E-08 7.05E-05 
developmental process 148 99.93 1.48 1.09E-07 8.58E-05 
positive regulation of cell death 34 12.10 2.81 1.42E-07 1.07E-04 
platelet degranulation 14 2.32 6.04 2.55E-07 1.83E-04 
negative regulation of metabolic process 87 50.25 1.73 3.98E-07 2.72E-04 
establishment of localization 125 81.72 1.53 4.22E-07 2.77E-04 
mRNA metabolic process 33 12.15 2.72 4.58E-07 2.88E-04 
animal organ development 93 55.82 1.67 6.29E-07 3.67E-04 
positive regulation of cell adhesion 24 7.19 3.34 6.22E-07 3.77E-04 
positive regulation of smooth muscle cell proliferation 11 1.52 7.23 1.00E-06 5.62E-04 
secretion 44 19.65 2.24 1.15E-06 6.23E-04 
biological adhesion 39 16.51 2.36 1.67E-06 8.77E-04 
transport 120 79.65 1.51 1.73E-06 8.79E-04 
cell adhesion 38 16.40 2.32 3.08E-06 1.52E-03 
RNA splicing, via transesterification reactions 19 5.29 3.59 3.44E-06 1.64E-03 
exocytosis 34 14.07 2.42 4.04E-06 1.82E-03 
positive regulation of cell proliferation 38 16.69 2.28 4.16E-06 1.82E-03 
multicellular organismal process 165 121.64 1.36 4.02E-06 1.86E-03 
response to lipid 36 15.30 2.35 5.08E-06 2.16E-03 
secretion by cell 39 17.56 2.22 6.63E-06 2.75E-03 
positive regulation of protein modification process 45 21.80 2.06 6.96E-06 2.81E-03 
regulation of cell adhesion 30 11.86 2.53 9.77E-06 3.50E-03 
regulation of molecular function 90 57.02 1.58 9.68E-06 3.54E-03 
positive regulation of cell migration 24 8.49 2.83 9.46E-06 3.54E-03 
positive regulation of phosphate metabolic process 42 20.04 2.10 9.37E-06 3.60E-03 
positive regulation of phosphorus metabolic process 42 20.04 2.10 9.37E-06 3.69E-03 
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 18 5.23 3.44 1.09E-05 3.74E-03 
mRNA splicing, via spliceosome 18 5.23 3.44 1.09E-05 3.82E-03 
positive regulation of cellular process 133 94.46 1.41 1.22E-05 4.07E-03 
negative regulation of nitrogen compound metabolic process 70 41.28 1.70 1.44E-05 4.72E-03 
RNA splicing 21 7.01 3.00 1.50E-05 4.74E-03 
female pregnancy 14 3.37 4.16 1.48E-05 4.76E-03 
negative regulation of gene expression 56 30.44 1.84 1.58E-05 4.86E-03 
positive regulation of cell motility 24 8.82 2.72 1.71E-05 5.16E-03 
embryo implantation 7 .72 9.66 1.82E-05 5.19E-03 
regulation of apoptotic process 52 27.78 1.87 1.76E-05 5.22E-03 
regulation of catalytic activity 69 40.63 1.70 1.79E-05 5.23E-03 
response to wounding 26 10.14 2.56 2.04E-05 5.73E-03 
regulation of cell death 55 30.24 1.82 2.34E-05 6.47E-03 
positive regulation of phosphorylation 39 18.76 2.08 2.48E-05 6.73E-03 
angiogenesis 18 5.61 3.21 2.65E-05 6.83E-03 
positive regulation of protein phosphorylation 38 17.93 2.12 2.65E-05 6.94E-03 
positive regulation of cellular component movement 24 9.07 2.65 2.64E-05 7.04E-03 
regulation of programmed cell death 52 28.05 1.85 2.86E-05 7.14E-03 
wound healing 23 8.51 2.70 2.84E-05 7.20E-03 
response to stimulus 190 149.45 1.27 3.48E-05 8.55E-03 
positive regulation of protein metabolic process 54 30.04 1.80 3.55E-05 8.58E-03 
regulation of cell motility 34 15.50 2.19 3.87E-05 9.23E-03 
positive regulation of protein kinase activity 24 9.32 2.57 4.01E-05 9.42E-03 
regulated exocytosis 29 12.51 2.32 4.23E-05 9.51E-03 
regulation of cell migration 32 14.49 2.21 4.33E-05 9.60E-03 
biological regulation 259 219.29 1.18 4.22E-05 9.64E-03 
response to organic substance 81 51.42 1.58 4.18E-05 9.68E-03 
response to hypoxia 17 5.34 3.18 4.83E-05 1.00E-02 
taxis 24 9.43 2.54 4.78E-05 1.00E-02 
protein metabolic process 114 79.92 1.43 4.72E-05 1.00E-02 
immune system process 76 47.66 1.59 4.68E-05 1.01E-02 
positive regulation of locomotion 24 9.42 2.55 4.64E-05 1.01E-02 
regulation of apoptotic signaling pathway 20 7.06 2.83 5.10E-05 1.04E-02 
response to heat 10 1.97 5.07 5.36E-05 1.05E-02 
negative regulation of cellular metabolic process 72 44.33 1.62 5.25E-05 1.06E-02 
response to oxygen levels 18 5.94 3.03 5.31E-05 1.06E-02 
ribonucleoprotein complex subunit organization 15 4.35 3.45 5.66E-05 1.07E-02 
nitrogen compound transport 56 31.96 1.75 5.64E-05 1.08E-02 
cellular response to stress 52 28.84 1.80 5.61E-05 1.09E-02 
basic amino acid transmembrane transport 4 .16 24.55 6.20E-05 1.16E-02 
cell activation 38 18.74 2.03 6.76E-05 1.25E-02 
regulation of protein phosphorylation 47 25.31 1.86 7.19E-05 1.27E-02 
response to decreased oxygen levels 17 5.52 3.08 7.13E-05 1.27E-02 
positive regulation of catalytic activity 47 25.26 1.86 7.07E-05 1.28E-02 
response to external stimulus 61 36.21 1.68 7.04E-05 1.29E-02 
multi-multicellular organism process 14 3.95 3.55 7.58E-05 1.31E-02 
regulation of biological quality 101 69.37 1.46 7.54E-05 1.32E-02 
positive regulation of cell-cell adhesion 15 4.49 3.34 8.02E-05 1.36E-02 
organonitrogen compound metabolic process 135 99.91 1.35 8.20E-05 1.36E-02 
regulation of intracellular signal transduction 57 33.26 1.71 7.96E-05 1.36E-02 
protein folding 14 3.98 3.51 8.31E-05 1.36E-02 
regulation of locomotion 35 16.88 2.07 8.18E-05 1.37E-02 
regulation of cellular component movement 35 16.97 2.06 8.64E-05 1.37E-02 
organonitrogen compound biosynthetic process 47 25.71 1.83 8.51E-05 1.38E-02 
cellular metabolic process 201 162.43 1.24 8.62E-05 1.38E-02 
response to organic cyclic compound 33 15.73 2.10 8.87E-05 1.40E-02 
regulation of protein metabolic process 78 50.21 1.55 9.37E-05 1.46E-02 
regulation of protein kinase activity 30 13.76 2.18 9.47E-05 1.46E-02 
cellular protein metabolic process 97 66.29 1.46 9.85E-05 1.48E-02 
vesicle-mediated transport 58 34.26 1.69 9.79E-05 1.48E-02 
regulation of protein catabolic process 19 6.83 2.78 9.73E-05 1.49E-02 
cellular component assembly 71 44.49 1.60 1.07E-04 1.58E-02 
regulation of developmental process 71 44.65 1.59 1.10E-04 1.60E-02 
positive regulation of cellular protein metabolic process 50 28.17 1.77 1.09E-04 1.61E-02 
response to temperature stimulus 12 3.13 3.83 1.25E-04 1.80E-02 
regulation of phosphorus metabolic process 53 30.71 1.73 1.37E-04 1.93E-02 
cellular component biogenesis 75 48.31 1.55 1.36E-04 1.93E-02 
regulation of phosphate metabolic process 53 30.67 1.73 1.36E-04 1.94E-02 
detection of stimulus involved in sensory perception 0 9.38 
< 
0.01 1.42E-04 1.98E-02 
cellular response to organic substance 65 40.31 1.61 1.50E-04 2.03E-02 
positive regulation of kinase activity 24 10.05 2.39 1.48E-04 2.04E-02 
regulation of cellular component organization 70 44.42 1.58 1.49E-04 2.04E-02 
mRNA processing 21 8.31 2.53 1.54E-04 2.08E-02 
positive regulation of leukocyte chemotaxis 8 1.43 5.59 1.60E-04 2.11E-02 
amino acid transmembrane transport 8 1.43 5.59 1.60E-04 2.13E-02 
symbiont process 27 12.02 2.25 1.70E-04 2.22E-02 
chemotaxis 23 9.40 2.45 1.72E-04 2.23E-02 
response to abiotic stimulus 38 19.79 1.92 1.76E-04 2.27E-02 
regulation of kinase activity 31 14.96 2.07 1.80E-04 2.29E-02 
positive regulation of cellular metabolic process 86 58.01 1.48 1.79E-04 2.30E-02 
positive regulation of biological process 141 107.05 1.32 1.84E-04 2.32E-02 
regulation of phosphorylation 48 27.20 1.76 1.89E-04 2.36E-02 
peptide metabolic process 23 9.56 2.41 1.96E-04 2.41E-02 
basic amino acid transport 4 .24 16.99 1.95E-04 2.42E-02 
protein targeting to ER 9 1.92 4.69 2.17E-04 2.63E-02 
organic substance transport 62 38.42 1.61 2.16E-04 2.63E-02 
nervous system development 65 40.76 1.59 2.24E-04 2.69E-02 
cellular localization 67 42.70 1.57 2.27E-04 2.71E-02 
protein localization to endoplasmic reticulum 10 2.39 4.18 2.33E-04 2.76E-02 
primary metabolic process 201 164.66 1.22 2.52E-04 2.94E-02 
regulation of MAPK cascade 29 13.67 2.12 2.51E-04 2.94E-02 
vasculature development 22 9.07 2.43 2.63E-04 3.05E-02 
regulation of transforming growth factor beta production 5 .51 9.86 2.73E-04 3.14E-02 
establishment of protein localization to endoplasmic reticulum 9 1.99 4.52 2.81E-04 3.15E-02 
metabolic process 215 178.98 1.20 2.80E-04 3.17E-02 
peptide biosynthetic process 19 7.46 2.55 2.87E-04 3.18E-02 
nitrogen compound metabolic process 192 156.12 1.23 2.79E-04 3.18E-02 
regulation of peptide transport 27 12.62 2.14 2.86E-04 3.19E-02 
cellular response to chemical stimulus 75 49.52 1.51 2.96E-04 3.25E-02 
apoptotic process 32 16.13 1.98 3.10E-04 3.37E-02 
cardiovascular system development 22 9.27 2.37 3.13E-04 3.37E-02 
regulation of hydrolase activity 41 22.69 1.81 3.09E-04 3.38E-02 
regulation of cellular protein metabolic process 70 45.61 1.53 3.33E-04 3.56E-02 
negative regulation of protein metabolic process 36 18.99 1.90 3.38E-04 3.59E-02 
actin cytoskeleton organization 21 8.56 2.45 3.55E-04 3.68E-02 
regulation of signal transduction 83 56.42 1.47 3.54E-04 3.69E-02 
nuclear-transcribed mRNA catabolic process 12 3.53 3.40 3.52E-04 3.70E-02 
response to ketone 12 3.53 3.40 3.52E-04 3.72E-02 
translation 18 6.99 2.58 3.63E-04 3.74E-02 
ribonucleoprotein complex assembly 13 4.09 3.18 3.75E-04 3.83E-02 
blood vessel development 21 8.65 2.43 3.77E-04 3.83E-02 
positive regulation of transferase activity 25 11.35 2.20 3.81E-04 3.84E-02 
response to oxygen-containing compound 46 26.73 1.72 3.91E-04 3.89E-02 
amide biosynthetic process 22 9.49 2.32 3.91E-04 3.91E-02 
regulation of protein modification process 53 32.21 1.65 4.08E-04 3.96E-02 
regulation of biological process 242 207.18 1.17 4.03E-04 3.97E-02 
regulation of transferase activity 33 16.95 1.95 4.01E-04 3.97E-02 
response to chemical 107 77.57 1.38 4.07E-04 3.98E-02 
positive regulation of leukocyte differentiation 10 2.59 3.86 4.25E-04 4.07E-02 
regulation of localization 72 47.57 1.51 4.23E-04 4.08E-02 
regulation of body fluid levels 21 8.85 2.37 4.44E-04 4.23E-02 
positive regulation of T cell activation 12 3.64 3.30 4.56E-04 4.25E-02 
organic acid transmembrane transport 9 2.14 4.21 4.54E-04 4.25E-02 
positive regulation of nitrogen compound metabolic process 82 56.04 1.46 4.50E-04 4.27E-02 
carboxylic acid transmembrane transport 9 2.14 4.21 4.54E-04 4.28E-02 
positive regulation of transforming growth factor beta production 4 .31 12.99 4.64E-04 4.29E-02 
leukocyte migration 17 6.54 2.60 4.73E-04 4.35E-02 
SRP-dependent cotranslational protein targeting to membrane 8 1.70 4.70 4.76E-04 4.36E-02 
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 9 2.15 4.18 4.81E-04 4.38E-02 
positive regulation of molecular function 52 31.42 1.66 4.85E-04 4.38E-02 
blood vessel morphogenesis 18 7.19 2.50 4.99E-04 4.38E-02 
regulation of mitochondrion organization 11 3.15 3.49 4.98E-04 4.40E-02 
detection of chemical stimulus involved in sensory perception 0 8.42 
< 
0.01 4.92E-04 4.40E-02 
protein-containing complex subunit organization 54 33.23 1.63 4.89E-04 4.40E-02 
interspecies interaction between organisms 27 12.84 2.10 4.96E-04 4.41E-02 
cell-cell signaling 35 18.74 1.87 5.07E-04 4.43E-02 
regulation of signaling 90 63.34 1.42 5.13E-04 4.46E-02 
response to glucocorticoid 10 2.66 3.76 5.20E-04 4.50E-02 
cell migration 32 16.57 1.93 5.63E-04 4.79E-02 
RNA processing 30 15.23 1.97 5.61E-04 4.79E-02 
response to steroid hormone 16 6.03 2.65 5.60E-04 4.82E-02 
      
      
GO molecular function complete # expected Fold raw P value FDR 
protein binding 289 212.99 1.36 1.51E-15 7.03E-12 
RNA binding 67 30.08 2.23 1.55E-09 1.81E-06 
molecular function 358 317.64 1.13 1.22E-09 1.89E-06 
binding 323 272.81 1.18 2.43E-09 2.26E-06 
Unclassified 23 63.36 .36 1.22E-09 2.83E-06 
identical protein binding 59 32.08 1.84 7.30E-06 5.66E-03 
growth factor binding 12 2.50 4.80 1.61E-05 1.07E-02 
cell adhesion molecule binding 23 8.73 2.64 4.11E-05 2.13E-02 
enzyme binding 68 40.85 1.66 3.97E-05 2.31E-02 
carbohydrate derivative binding 67 40.43 1.66 5.28E-05 2.46E-02 
hydrolase activity, acting on acid anhydrides 34 16.59 2.05 1.23E-04 2.73E-02 
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 34 16.59 2.05 1.23E-04 2.87E-02 
glycosaminoglycan binding 14 4.00 3.50 8.70E-05 2.89E-02 
pyrophosphatase activity 34 16.53 2.06 1.19E-04 2.92E-02 
basic amino acid transmembrane transporter activity 4 .20 20.08 1.15E-04 2.98E-02 
amino acid transmembrane transporter activity 8 1.34 5.97 1.05E-04 3.06E-02 
anion binding 78 50.46 1.55 9.95E-05 3.09E-02 
cytoskeletal protein binding 35 16.97 2.06 8.64E-05 3.09E-02 
protein phosphatase activator activity 4 .20 20.08 1.15E-04 3.15E-02 
nucleoside-triphosphatase activity 33 15.66 2.11 8.31E-05 3.23E-02 
protein-containing complex binding 38 19.08 1.99 8.17E-05 3.46E-02 
      
      
GO cellular component complete # expected Fold raw P value FDR 
intracellular organelle part 252 166.35 1.51 2.56E-18 5.19E-15 
organelle 320 243.61 1.31 1.15E-17 7.77E-15 
organelle part 256 171.67 1.49 8.34E-18 8.46E-15 
membrane-bounded organelle 302 223.91 1.35 5.30E-17 2.69E-14 
intracellular organelle 305 228.65 1.33 1.48E-16 6.01E-14 
intracellular part 330 261.15 1.26 5.55E-16 1.61E-13 
cytoplasm 286 208.23 1.37 4.85E-16 1.64E-13 
cytoplasmic part 252 174.64 1.44 3.33E-15 8.45E-13 
intracellular 331 266.17 1.24 1.58E-14 3.56E-12 
intracellular membrane-bounded organelle 266 196.46 1.35 8.18E-13 1.66E-10 
Unclassified 6 41.93 .14 2.62E-12 4.43E-10 
cellular component 375 339.07 1.11 2.62E-12 4.83E-10 
cell 356 308.39 1.15 7.65E-12 1.19E-09 
extracellular space 113 59.84 1.89 1.48E-11 2.00E-09 
extracellular region part 117 63.23 1.85 1.67E-11 2.11E-09 
cell part 355 307.90 1.15 1.48E-11 2.14E-09 
extracellular exosome 80 37.93 2.11 2.94E-10 3.32E-08 
vesicle 120 68.52 1.75 2.84E-10 3.39E-08 
extracellular organelle 80 38.33 2.09 3.92E-10 3.98E-08 
extracellular vesicle 80 38.30 2.09 3.80E-10 4.06E-08 
membrane-enclosed lumen 150 94.59 1.59 5.79E-10 5.11E-08 
intracellular organelle lumen 150 94.59 1.59 5.79E-10 5.34E-08 
organelle lumen 150 94.59 1.59 5.79E-10 5.59E-08 
endomembrane system 132 80.25 1.64 1.38E-09 1.16E-07 
cytosol 145 91.86 1.58 2.53E-09 2.06E-07 
extracellular region 126 77.89 1.62 1.40E-08 1.10E-06 
focal adhesion 27 7.32 3.69 1.77E-08 1.33E-06 
cell-substrate adherens junction 27 7.37 3.66 2.04E-08 1.48E-06 
cell-substrate junction 27 7.44 3.63 2.47E-08 1.73E-06 
intracellular vesicle 79 41.52 1.90 3.40E-08 2.23E-06 
cytoplasmic vesicle 79 41.46 1.91 3.31E-08 2.24E-06 
protein-containing complex 146 97.54 1.50 6.40E-08 4.06E-06 
intracellular non-membrane-bounded organelle 121 75.98 1.59 6.95E-08 4.27E-06 
non-membrane-bounded organelle 121 76.10 1.59 7.24E-08 4.32E-06 
pigment granule 13 1.90 6.84 1.87E-07 1.06E-05 
melanosome 13 1.90 6.84 1.87E-07 1.09E-05 
adherens junction 29 9.74 2.98 4.04E-07 2.21E-05 
anchoring junction 29 10.03 2.89 7.13E-07 3.81E-05 
cytoplasmic vesicle part 52 26.71 1.95 7.06E-06 3.67E-04 
membrane 220 175.85 1.25 7.72E-06 3.91E-04 
myelin sheath 13 2.95 4.40 1.69E-05 8.36E-04 
secretory granule 34 15.12 2.25 1.79E-05 8.64E-04 
cytoplasmic vesicle lumen 19 6.08 3.12 2.24E-05 1.06E-03 
vesicle lumen 19 6.10 3.11 2.33E-05 1.07E-03 
cell surface 35 15.99 2.19 2.85E-05 1.28E-03 
whole membrane 54 29.60 1.82 2.95E-05 1.30E-03 
cell junction 45 23.10 1.95 3.33E-05 1.44E-03 
collagen-containing extracellular matrix 16 4.67 3.43 3.52E-05 1.49E-03 
secretory vesicle 37 17.87 2.07 4.65E-05 1.92E-03 
endocytic vesicle 17 5.38 3.16 5.23E-05 2.12E-03 
vacuole 31 13.98 2.22 5.52E-05 2.20E-03 
cytoskeleton 65 39.26 1.66 6.27E-05 2.45E-03 
extracellular matrix 21 7.84 2.68 7.11E-05 2.72E-03 
nuclear lumen 106 74.09 1.43 8.80E-05 3.30E-03 
ribonucleoprotein complex 33 15.81 2.09 9.49E-05 3.50E-03 
nuclear part 114 81.30 1.40 1.15E-04 4.18E-03 
secretory granule lumen 17 5.79 2.93 1.24E-04 4.41E-03 
organelle membrane 81 53.16 1.52 1.37E-04 4.79E-03 
ficolin-1-rich granule lumen 10 2.25 4.45 1.45E-04 4.99E-03 
chromosome 36 18.31 1.97 1.62E-04 5.48E-03 
spliceosomal complex 12 3.30 3.64 1.94E-04 6.46E-03 
nucleus 167 132.14 1.26 2.69E-04 8.80E-03 
cytosolic large ribosomal subunit 7 1.20 5.86 3.17E-04 1.02E-02 
vacuolar part 23 10.09 2.28 3.42E-04 1.08E-02 
bounding membrane of organelle 60 37.44 1.60 3.57E-04 1.12E-02 
lytic vacuole 26 12.15 2.14 3.78E-04 1.13E-02 
actin filament bundle 7 1.23 5.69 3.74E-04 1.13E-02 
lysosome 26 12.13 2.14 3.71E-04 1.14E-02 
nucleoplasm 90 63.12 1.43 4.99E-04 1.47E-02 
cytosolic ribosome 9 2.19 4.11 5.39E-04 1.56E-02 
vacuolar membrane 18 7.28 2.47 5.74E-04 1.62E-02 
cytoskeletal part 50 30.29 1.65 5.73E-04 1.64E-02 
microtubule cytoskeleton 38 21.57 1.76 1.11E-03 3.05E-02 
endoplasmic reticulum 54 34.19 1.58 1.10E-03 3.05E-02 
cytosolic part 13 4.65 2.79 1.16E-03 3.15E-02 
chromosomal part 30 16.08 1.87 1.29E-03 3.44E-02 
ribosomal subunit 11 3.60 3.05 1.41E-03 3.71E-02 
endoplasmic reticulum lumen 14 5.43 2.58 1.58E-03 4.12E-02 
VCP-NSFL1C complex 2 .04 55.23 1.85E-03 4.69E-02 
platelet alpha granule 7 1.65 4.25 1.84E-03 4.73E-02 
nuclear body 26 13.53 1.92 1.97E-03 4.94E-02 
 
